close

health care

Prescription drugs

Most Commonly Misused Prescription Drugs in the United States

Cloth

Most Commonly Misused Prescription Drugs in the United States

The Substance Abuse and Mental Health Services Administration, or SAMHSA, reported that among people who abused prescription painkillers in 2020, nearly 65% ​​said their main reason for doing so was to relieve physical pain. The percentage of people reporting drug abuse as a reason for getting high was 11.3%.

Abuse is defined as patients who take prescription drugs in a manner other than that recommended by their doctor. It may be like taking someone else’s prescription or taking their own in larger or more frequent doses, or for a longer period of time.

Citing data from SAMHSA, Zinnia Health identified the most commonly used prescription medications in the United States, all of which are opioid pain relievers or opioid pain relievers. This class of drugs acts on the central nervous system by blocking pain signals to the brain. In addition to relieving pain, these drugs also intensely trigger the brain’s reward centers, releasing endorphins and creating positive feelings commonly referred to as euphoria. This is what makes prescription opioids – and all opioids, for that matter – so dangerously addictive.

Prolonged use of opioids may increase a patient’s tolerance to a particular drug. With higher tolerance, the drug becomes less effective and patients do not experience the same level of pain relief and feelings of euphoria, which often leads people to seek out stronger opioids. This could explain why such a large percentage of people reported misusing prescription opioids for pain relief. For example, someone who has abused and developed a tolerance to morphine may seek something stronger like oxycodone or hydromorphone, whose effects kick in faster and more intensely.

SAMHSA also found that nearly half of people who abused painkillers (47.2%) said they got the drugs from a friend or relative, either by stealing them, buying them, or getting them for free. . About 44% of people said they got prescriptions from a health care provider. Drug diversion—or the disruption of a prescription drug along its legal, intended journey from manufacturer to physician to patient—is a contributing factor to drug abuse. Diversion occurs, among other things, through doctor purchases, theft and tampering.

The United States is in its third wave of the opioid crisis, but it is important to note that this current wave is characterized by illicitly produced synthetic opioids. Overdose deaths from commonly prescribed opioids have declined in recent years. However, knowing the uses and risks associated with these drugs can save lives. Read on to learn about the most commonly used prescription drugs in the United States.



MedStock Photos // Shutterstock

#8. Morphine

– Abuse in the past year (former users): 8.9%
– Misuse in the past year (general population): 0.2%

Known by its brand names Avinza or Kadian, morphine is an opioid used to treat acute and chronic pain. Although morphine can be given intravenously, it is most often taken as tablets or capsules. Morphine is closely related to other painkillers like hydrocodone and oxycodone. The potency of other opioids is often determined or compared against the potency of morphine.



chatuphot // Shutterstock

#7. Tramadol

– Abuse in the past year (former users): 9.0%
– Misuse in the past year (general population): 0.5%

Tramadol, commonly referred to by its brand name Ultram, is a synthetic opioid used to treat moderate to severe pain, usually after surgery. The drug is commonly prescribed in the form of extended-release tablets to relieve severe chronic pain caused by conditions such as fibromyalgia. In 2019, approximately 5.5 million people were prescribed Tramadol, totaling almost 20 million prescriptions. It was the 35th most prescribed drug in the United States



Joe Mamer // Shutterstock

#6. Codeine

– Misuse in the past year (former users): 12.2%
– Misuse in the past year (general population): 0.9%

Codeine is an opioid used to treat mild to moderate pain and is most commonly prescribed as a cough suppressant. It can also be used to treat gastrointestinal issues like diarrhea. Because codeine is milder than other opioids, users with misuse intentions increase doses to achieve a higher high. Codeine abuse can lead to more intense opioid abuse.



Cloth

#5. Hydrocodone

– Misuse in the past year (former users): 12.6%
– Misuse in the past year (general population): 1.7%

Hydrocodone is the most frequently prescribed opioid in the United States In 2020, 4.7 million people misused hydrocodone products, making it the most commonly used type of prescription pain reliever this that year. Hydrocodone, also known by its brand name Vicodin, is given to patients with moderate to severe pain, usually after surgery or injury, or to relieve pain associated with medical conditions such as cancer. In combination with homatropine, hydrocodone can also be used as an antitussive. Unlike other opioids, hydrocodone is not often illicitly manufactured and the vast majority of diverted hydrocodone is pharmaceutical.



Cloth

#4. Oxycodone

– Abuse in past year (former users): 14.5%
– Misuse in the past year (general population): 1.1%

Oxycodone is an opioid prescribed to treat persistent severe pain. OxyContin and Percocet are two of the most recognizable brands, the former being a pure form of oxycodone and the latter a combination of oxycodone and aspirin. About 3.2 million people abused oxycodone products in 2020, making it the second most misused painkiller behind hydrocodone. Oxycodone abuse is prevalent across the spectrum of geographic, demographic, and socioeconomic conditions.



PureRadiancePhoto // Shutterstock

#3. Fentanyl

– Misuse in the past year (former users): 14.8%
– Misuse in the past year (general population): 0.1%

The pharmaceutical fentanyl, which this data refers to, can be up to 100 times more potent than morphine and is most commonly used to treat pain associated with advanced cancer. Legally produced fentanyl is usually given in the form of patches or lozenges. According to the Drug Enforcement Administration, misuse of these products may include ingesting the gel inside the patches or freezing the patches, cutting them into pieces, and placing them inside the cheek to absorb the contents. . Because a percentage of fentanyl remains in used patches even after three days of use, used patches are also targeted for misuse. Illegally manufactured, non-pharmaceutical fentanyl is at the heart of the third and current wave of the opioid epidemic in the United States.



Cloth

#2. Hydromorphone

– Misuse in the past year (former users): 16.6%
– Misuse in the past year (general population): 0.1%

Hydromorphone, commonly referred to by the brand names Dilaudid or Exalgo, is an opioid prescribed to treat severe pain in patients resistant to less potent opioids. It is about eight times stronger than morphine and the effects of a 1-2 mg dose can be felt in as little as 15 minutes. Hydromorphone carries a high risk of addiction and is only prescribed in certain medical circumstances, such as cancer pain management or cancer-related treatment. According to the Drug Enforcement Administration, hydromorphone was once the most commonly misused or misused drug, now supplanted by oxycodone and hydrocodone.



PureRadiancePhoto // Shutterstock

#1. Buprenorphine

– Abuse in the past year (former users): 26.5%
– Misuse in the past year (general population): 0.2%

Buprenorphine is an opioid used in the drug treatment of opioid use disorder, or OUD, specifically to reduce intense withdrawal symptoms that can lead to relapse. It works by stimulating the brain in the same way as heroin or methadone, but to a lesser degree, creating a limit to its effects. It can produce euphoria without the risk of suppressing breathing, which is the true cause of death in opioid overdose. Since prolonged use of opioids inhibits the brain’s ability to produce dopamine on its own, the right dosage of buprenorphine and a comprehensive treatment plan allow patients with OUD to feel “normal” or equilibrium.

This story originally appeared on Zinnia Health
and was produced and distributed in partnership with Stacker Studio.


read more
Prescription drugs

10 prescription drugs that cost Medicare the most


“You certainly envision a significant impact on Medicare Part D spending, both on the program and on beneficiaries,” says Leigh Purvis, AARP’s director of healthcare cost and access. “It’s indicative of the larger problem where we’ve left pharma companies free to continue to engage in the kind of pricing behavior that has been problematic for so long.” New data from AARP shows that in January 2022, the average list price increase for the top 75 brand name drugs was 5.2%. Price increases ranged from 2% to 7.9%, and the prices of more than half (42 of 75) increased by 5% or more.As

AARP’s Fair Rx Prices Now campaign has worked to convince lawmakers to allow Medicare to negotiate prices with pharmaceutical manufacturers, impose tax penalties on drug manufacturers who raise prices more than the inflation and to cap Part D disbursements.

Here’s a look at the 10 drugs Medicare spent the most money on in 2020 and whose prices rose in January 2022.

1. Equip

  • Use: A blood thinner for people with atrial fibrillation (A-fib)
  • Health insurance expenditure in 2020: $9.9 billion
  • Number of beneficiaries: 2,641,941
  • January 2022 price increase: 6 percent

2. Revlimid

  • Use: To treat cancer
  • Health insurance expenditure in 2020: $5.4 billion
  • Number of beneficiaries: 43,747
  • January 2022 price increase: 4.5%

3. Xarelto

  • Use: A blood thinner for people with atrial fibrillation (A-fib)
  • Health insurance expenditure in 2020: $4.7 billion
  • Number of beneficiaries: 1,184,718
  • January 2022 price increase: 4.9%

4. Januvia

  • Use: To treat diabetes
  • Health insurance expenditure in 2020: $3.9 billion
  • Number of beneficiaries: 934 686
  • January 2022 price increase: 5 percent

5. Truth

  • Use: To treat diabetes
  • Health insurance expenditure in 2020: $3.3 billion
  • Number of beneficiaries: 497 327
  • January 2022 price increase: 5 percent

6. Imbruvic

  • Use: To treat cancer
  • Health insurance expenditure in 2020: $3 billion
  • Number of beneficiaries: 26,847
  • January 2022 price increase: 7.4%

7. Gardening

  • Use: To treat diabetes
  • Health insurance expenditure in 2020: $2.4 billion
  • Number of beneficiaries: 594 859
  • January 2022 price increase: 4 percent

8. Humira Pen (Cf)

  • Use: To treat rheumatoid arthritis, plaque psoriasis
  • Health insurance expenditure in 2020: $2.2 billion
  • Number of beneficiaries: 42,406
  • January 2022 price increase: 7.4%

9. Ibrance

  • Use: To treat cancer
  • Health insurance expenditure in 2020: $2.1 billion
  • Number of beneficiaries: 21,394
  • January 2022 price increase: 6.9%

10. Symbicort

  • Use: To treat asthma
  • Health insurance expenditure in 2020: $2 billion
  • Number of beneficiaries: 1,017,530
  • January 2022 price increase: 2 percent

Dena Bunis covers Medicare, health care, health policy and Congress. She also writes the “Medicare Made Easy” column for the AARP Newsletter. An award-winning journalist, Bunis has spent decades working for metropolitan dailies, including as Washington bureau chief for the Orange County Register and as a health and workplace policy maker for press day.

read more
Medical products

“Shortage” of medical products in Ukraine – WHO

There is a “shortage” of essential medical supplies in Ukraine, health officials have warned in condemning at least 16 attacks on health services in the country.

The World Health Organization (WHO) said there had been 16 attacks on health services, including damage to facilities and hospitals, as well as the commandeering of ambulances and the hijacking of ambulances from ’emergency.

These attacks left nine dead and 16 injured, according to the WHO.

The European branch of the global health body also said there was a shortage of essential supplies in Ukraine, including oxygen, insulin, surgical supplies and blood.

(PA graphics)

(PA graphics)

Experts have also warned that Covid deaths will rise due to a lack of oxygen supply in the region – with 731 deaths reported last week.

Meanwhile, health officials have raised concerns about cases of hypothermia – where a person’s body temperature becomes dangerously low – among refugees in cold weather.

They also highlighted fears over maternity care for pregnant Ukrainian women, with around 80,000 women expected to give birth in the country in the next three months.

During a press briefing on the humanitarian crisis that resulted from the conflict, Dr Hans Henri Kluge, WHO Regional Director for Europe, said: “It is now 13 days since the military offensive began in Ukraine, and today in the country, we see a healthcare system under great pressure, and beyond its borders, the fastest growing refugee crisis in Europe for more than 75 years.

“Life-saving essential medicines, such as oxygen and insulin, personal protective equipment, surgical supplies, anesthetics and safe blood products, are in short supply.”

He said 76 tons of trauma and emergency health supplies are in transit in Ukraine, with more on the way.

WHO is also working to ensure that refugees crossing the border have access to health care and that those who remain in the country also receive support.

Dr Kluge added: “It should not be necessary to say that health workers, hospitals and other medical establishments should never be a target at any time, including during crises and conflicts. To date, we have 16 confirmed reports of health incidents in Ukraine, with more being verified.



We know from previous conflicts that when more doors close, health diplomacy becomes key

Dr Hans Henri Kluge, WHO Regional Director for Europe

“WHO strongly condemns these attacks on health services.”

Dr Catherine Smallwood, WHO Europe Incident Manager for Covid-19, said: “We have documented or verified 16 attacks with varying levels of certainty.

“These have, to our knowledge, caused at least nine deaths and 16 injuries, and they have occurred in various major cities and around conflict zones.

“This includes direct attacks on health facilities or hospitals that have been damaged.

“It also includes the appropriation of health infrastructure such as ambulances, it includes the diversion of ambulances and their use for purposes not directly related to the provision of health care.”

Dr Kluge praised Ukrainian health officials for continuing to monitor the spread of Covid-19, but added that “731 Covid-19 deaths were reported to WHO from Ukraine last week, and unfortunately, that number will increase as oxygen shortages continue.”

He said: “Older people will be disproportionately affected because their access to healthcare is disrupted and because only a third of those over 60 are fully protected with a full course of vaccines.”

Asked about the humanitarian corridors, Dr Kluge said: “Time is running out, so in that sense, willy-nilly, we need to get whatever we can to the affected areas.

(PA graphics)

(PA graphics)

“We know from previous conflicts that when more doors close, health diplomacy becomes key.

“Our principle is health for all and our top priority is to get life-saving humanitarian medical supplies to people in need.”

On maternity care, Dr Isabel Yordi Aguirre, WHO Europe Technical Officer for Gender and Human Rights, said: “The estimate from UNFPA (United Nations Population Fund ) that 80,000 women will give birth in the next three months in Ukraine means that these women may have gone from a life-changing experience to a life-threatening experience.

“The UNHCR (UN Refugee Agency) predicts that by July this year we will have four million refugees, which will mean around 1,000 births per week that will be anticipated.

“That’s why we must ensure that sexual and reproductive health services are at the heart of our assistance to women – refugees crossing borders and women left behind.”

Tarik Jasarevic, WHO Field Representative in Ukraine, said at the briefing: “It is heartbreaking to see hundreds, if not thousands, of people on the border between Ukraine and Poland – mainly women and children seeking treatment and seeking safety.



Health facilities need supplies, they need electricity, they need water

Tarik Jasarevic, WHO representative in Ukraine

He added: “In the east, hundreds of health facilities are either areas that have changed control or are along the battle lines or within 10 kilometers of them.

“Health facilities need supplies, they need electricity, they need water.

“I have just spoken to a doctor who is in contact with his colleagues in the most affected areas in the East and she was telling me that people cannot access health centers and hospitals because of security and the structural damage.

“And this is not just the case for patients but also for health workers who risk their lives to get to their place of work.”

read more
Prescription drugs

Rising cost of prescription drugs is a concern | News

WASHINGTON, DC – Although current prices have recently skyrocketed due to inflation and global issues, they pale in comparison to the rise in prescription drugs.

“For years, increases in prescription drug prices have eclipsed even the highest rates of inflation,” said Holly Holtzer, director of Ohio AARP.

“To give you an example, if consumer prices had risen as fast as drug prices over the past 15 years, gasoline would now cost $12.20 a gallon and milk $13 a gallon,” he said. she added.

Holtzer said last month that major drugmakers had hiked prices on 800 prescription drugs.

“They’ve imposed similar increases for decades with no effective way to stop them from raising prices for American seniors,” Holtzer said.

She said her organization frequently hears of older Americans in Ohio having to choose whether to pay for medicine or for food and heat.

In an attempt to alleviate the problem, U.S. Senator Sherrod Brown, D-Ohio, introduced the Affordable Medicines Act, which would penalize drug companies that raise the price of their drugs without justification and also end the restriction that prevents Medicare to negotiate lower prices. prizes for beneficiaries.

“It is no mistake that current law protects the profits of Big Pharma, to the direct detriment of patients, by prohibiting the government from negotiating better prices for the American people,” Brown said. “The pharmaceutical companies were in the room when this law was written.”

Holtzer said giving Medicare the ability to negotiate would lower prices.

Brown also supports other efforts to reduce the cost of health care for workers in Ohio by capping the cost of insulin at $35 per month, imposing penalties on drugmakers who raise prices at above inflation and capping out-of-pocket expenses for Medicare beneficiaries at $2,000 per month. year.

“The point of prescription drugs is to allow (people) to live longer, healthier lives, not to make a bunch of drug company executives in New Jersey and elsewhere much richer,” Brown said.

“Congress has promised for years to lower the price of prescription drugs,” Holtzer said. “For any member of Congress concerned about inflation, lowering drug prices should be high on the to-do list.”

On Wednesday, Ohio AARP presented members of Congress with a petition signed by 182,000 Ohioans calling on lawmakers to act on prescription drug prices.

read more
Generic drugs

Savings on Generic Drugs Continue to Grow, Says Canadian Pharmacy Intermediary SaveRxCanada.to

VANCOUVER, BC, March 3, 2022 /PRNewswire/ — SaveRxCanada.to, a Leading Canadian Pharma Intermediary Since 2002, Continues to See an Uptrend Among Americans buy generic drugs. Generic drugs contain the same active ingredients with the same strength and purity as their brand name counterparts, but at a fraction of the cost.

the Rx Select The SaveRxCanada program was one of the first programs of its kind launched in 2004 to provide access to generic drugs. By adding several international pharmacies to their network, patients were able to find many generic and branded drugs not available in Canada.

The RxSelect program offers free shipping and 5% in rewards points that can be redeemed on future orders.

In United States76 million patients consult at least one prescription drug in 2020.

the 2021 U.S. Generic and Biosimilar Drug Savings Report highlighted the increased cost savings on generic drugs. Some key research findings:

  • $338 billion: US healthcare system savings
  • 90%: Portion of U.S. prescriptions filled with generic drugs
  • $6.61: The average generic share
  • $7.9 billion: savings on biosimilars
  • $109.6 billion: Medicare savings

The savings of individual consumers and the health care system as a whole continue to grow, reaching $338 billion in 2020. Tens of millions of Americans trust their health to generics and biosimilars. These savings are the main component of an often overlooked success story in public health.

About SaveRxCanada.to

SaveRxCanada.to has been a reliable, affordable and reliable Canadian pharmaceutical intermediary for over 18 years.

The company is committed to providing affordable prescription drugs to patients around the world through its network of licensed Canadian pharmacies and international pharmacies.

Visit SaveRxCanada.to to learn more about the company.

Customer service

Toll free: 1-866-799-3435 – Use reference #100048
Monday Friday 9:00 a.m. to 5:00 p.m. (EST)

All orders required a valid prescription from a licensed physician or physician.

This press release was published via 24-7PressRelease.com. For more information, visit http://www.24-7pressrelease.com.

SOURCESaveRxCanada.com

read more
Prescription drugs

Letter to the Editor – About Prescription Drugs | Opinion

As a Registered Nurse with decades of professional experience, I have provided health care to hundreds of rural Iowas. From treating traumatic injuries to chronic disease care to helping patients manage medications, we healthcare providers gain valuable insight into the inner workings of one of the largest sectors of the economy. And sometimes that hands-on experience and training in healthcare can be incredibly frustrating.

The high cost of life-saving drugs and prescription drugs is at the top of my list of concerns. I’m not alone. 83% of Americans say the cost of prescription drugs is unreasonable, according to an October 2021 public opinion poll conducted by the nonpartisan health care organization Kaiser Family Foundation (KFF).

The KFF poll also shows strong, bipartisan public support – more than 80% in favor – for government actions that:

facilitate the marketing of generic drugs

limit the drug company’s ability to raise prices above inflation

limit out-of-pocket spending for people on Medicare

allow governments to negotiate with pharmaceutical companies for lower prices on Rx drugs covered by Medicare and private insurance

Federal action to implement these grassroots policy changes has been blocked primarily by Senate Republicans and filibuster rules that Democrats seem unwilling to change.

Fortunately, we have an opportunity here in Iowa this legislative session to make prescription drugs more affordable and accessible. House File 263 would cap the cost of insulin at $100 per month for state-regulated health care plans in Iowa. House File 262 would allow those who need insulin, Epi-Pens and inhalers to receive emergency prescriptions from their pharmacist if their doctor is unavailable for a prescription. Both bills would help tens of thousands of Iowans.

Both of these bills passed the Iowa House of Representatives last year 91-0 and 89-2. Unfortunately, the state senate took no action. Sen. Jeff Edler (R, State Center), who chairs the Senate Human Resources Committee, declined to schedule votes on these incredibly popular and important bills.

Senator Edler is certainly aware of his role in this process. For example, regular Iowans who rely on insulin to manage their diabetes have called and met with Senator Edler to implore him to allow a yes or no vote on these issues. Senator Edler needs to stop playing political games with people’s lives. After all, over 10% of adults in Iowa have diabetes, with diabetes rates over 20% for Iowans earning less than $25,000 a year.

If Senator Edler isn’t supporting Iowans with diabetes, who is he protecting? U.S. Senator Charles Grassley (R-IA), who was a key leader of Edler’s party for half a century, led an investigation into how drug companies measured insulin prices in 2019 when Grassley was Chairman of the Senate Finance Committee. The Grassley Committee report found that pharmaceutical companies Eli Lilly, Sanofi and Novo Nordisk have dramatically increased the prices of long- and short-acting insulins over the past decade, in some cases by more than 70% by only 5 years old.

It’s not a complicated question. To refuse to provide basic cost controls for life-saving prescription drugs is simply cruel and cynical policy. Pharmaceutical companies are among the most profitable companies in the world. Our political leaders, both in Washington DC and here at the Des Moines Statehouse, have allowed corporate power to block grassroots reform for too long. Now is the time to act, and it starts with Senator Edler scheduling a vote on House Items 262 and 263 before it’s too late during this year’s legislative session.

Barb Kalbach is a 4th generation family farmer, registered nurse, and board member of Iowa Citizens for Community Improvement. Barb can be reached at [email protected]

read more
Medical supplies

Ukraine Assistance: Vienna sends trucks with medical supplies to Kyiv and Odessa – Vindobona.org

The man is in uniform with his wife and daughter in front of their burning house. Here, the soldier could no longer protect his family. The Red Cross became the main relief association and in 1917 received the only Nobel Peace Prize during the war years. / Photo: © Wikimedia Commons / Eybl, Plakatmuseum Wien/Wikimedia Commons / CC BY-SA 4.0

The fact that the aid material donated by Vienna consists mainly of medical products such as FFP2 masks as well as protective equipment for hospital staff is somewhat reminiscent of the 5,000 helmets that the world’s fourth largest economy, Germany, wanted give to the Ukrainians. .

According to information from the city government, three trucks carrying relief supplies are already on their way to the war zone.

When loading, Mayor Michael Ludwig stressed that Vienna stands for cohesion and unity.

“The images reaching us today from Ukraine are deeply moving. It is a sad and deeply depressing day. Our thoughts are first and foremost with the innocent civilians who are the main victims. Austria is perhaps neutral in international law, but we are not neutral when it comes to our values. That is why Vienna is also ready to help people in need.”

“Especially in the current situation, it is important that we show solidarity,” continued Ludwig. “Let us reflect on the humanitarian traditions of our history and bring solidarity aid!”

He also highlighted the close urban network between Vienna and Ukraine. “Especially in an international crisis like the one we are currently experiencing, Vienna is there to help people.”

“Vienna has been involved in Ukraine for a long time, even independently” of the current crisis,” Ludwig explained.

Among other things, associations and organizations such as Caritas and Volkshilfe have been helping for years in the fields of education and health care, as well as in the treatment of drinking water in eastern Ukraine.

“We will continue to expand these aid programs in the future,” Ludwig said. He also said the city has already ordered more aid trucks. In the coming weeks, seven more trucks are expected to travel to Ukraine.

Vienna City Hall – Magistrate of the Stadt Wien

read more
Prescription drugs

Representative Glenn backs plan to reduce Michigan prescription drug costs


Representative Annette Glenn, R-Midland, continued her work to reduce prescription drug costs in Michigan.

Glenn voted in favor of House Bill 4348, which will help patients save on drug prices by reforming regulations and improving transparency related to Pharmacy Benefit Managers (PBMs). The legislation passed the House with overwhelming bipartisan support and advances to Governor Whitmer for his consideration.

“Michigan families are grappling with the rising cost of prescription drugs,” Glenn said. “This is an important step to help bring prices under control so people can get the medicines they need for themselves, their children and their parents.”


PBMs act as intermediaries between health plans, drug manufacturers and pharmacists. The PBM industry’s unregulated practices have contributed to the rising prices consumers pay for prescription drugs. House Bill 4348 would provide specific requirements for PBMs to improve transparency and combat unfair trade practices that unnecessarily increase drug prices.

The reforms target additional fees charged retroactively to pharmacies, discriminatory purchase limits and price increases for certain pharmacies, and restrictions that prevent pharmacies from providing relevant medical information to patients or discussing and selling alternatives. less expensive.

The measure is just one of the many ways Glenn is fighting to make health care more affordable. She co-sponsors House Bill 4346, which would reduce out-of-pocket expenses for many diabetics who need insulin. Insurance companies could charge no more than $50 for each 30-day supply.

read more
Medical supplies

Zipline expands drone medical supply deliveries to Kenya

Zipline, a global leader in instant logistics, is launching operations in another African country with on-demand drone deliveries of medical supplies to Kisumu County in Kenya.

Under the agreement between the two parties, Zipline will establish a mode of operation similar to that originally rolled out in Rwanda in 2016, and has since improved and expanded through partnerships with Ghana, Nigeria and Côte d’Ivoire. ‘Ivory. Once its storage and flight management center in Kenya is ready, Zipline will conduct automated drone flights of medicines and supplies to health facilities in Kisumu County.

The link is another example of how officials across Africa have turned to Zipline to create regular drone delivery networks of medical supplies to remote or hard-to-reach areas that often need them the most. . It’s part of a rapidly spreading ambition across the continent to create universal healthcare by taking treatment by air to underserved locations.

“We have made great efforts to improve the overall delivery of health care to our people,” said Kisumu County Governor, HE Prof. Anyang’ Nyong’o. “It is therefore heartening to note that our mission to achieve universal health coverage is well on its way with this historic partnership which will ensure that no one is left behind because of their location.”

Under the agreement, the new UAV logistics center in Kisumu County – a member of the Lake Region Economic Bloc (LREB) representing 14 million people, or 30% of Kenya’s population, will gradually serve health projects and clinics in 16 other western counties as well.

“It is our commitment as LREB to deliver an aggressive program of building a robust health care delivery system that will serve not just the few, but the vast majority of people in LREB counties,” said LREB Chairman Wycliffe Oparany. “Zipline’s technology is one we can use to accelerate the transformation of our healthcare systems to deliver timely healthcare solutions to the people whose mandate we serve.”

Once the new Zipline Logistics Center is operational, it will oversee on-demand drone deliveries of up to 1.8 kg of blood products, COVID-19 vaccines and other potentially life-saving medical supplies. The drone can cruise up to 110 km/h on round trips of up to 160 kilometers, even in adverse weather conditions, and it will operate seven days a week to ensure that healthcare payloads reach their destination in 30 minutes.

In addition to just-in-time deliveries of urgent medications, routine flights of medical supplies by Zipline drones will help facilities avoid running dangerously low on supplies.

“We’ve seen how on-demand automated delivery can transform healthcare systems to make them more efficient, effective and equitable,” said Keller Rinaudo, CEO of Zipline, which also operates in the United States. “Zipline’s expansion into Kenya, our seventh country, in partnership with Kisumu County, is a critical step in extending these important benefits to more communities around the world.”


Subscribe to DroneDJ on YouTube for exclusive videos

read more
Prescription drugs

D’Augusta – Ensuring Access to Prescription Medicines and Protecting Mainers

In our community, I know many of us are concerned about the cost of health insurance and the availability of life-enhancing or life-saving drugs. This year alone, pharmaceutical companies have raised the wholesale and retail prices of 450 drugs. When it comes to drug availability, recent surveys have found doctors and physicians struggling with cumbersome prior authorization protocols that slow or restrict their ability to prescribe drugs to their patients.

Anne Carney

Fortunately, two of my colleagues — Sen. Heather Sanborn (D-Portland) and Rep. Amy Roeder (D-Bangor) — have introduced bills to help protect Mainers from an unfair practice that some insurance companies use and to ensure that patients can obtain their prescription drugs.

Sanborn’s bill would protect Mainers from double billing. For those who don’t know, double billing occurs when a patient’s insurance company uses a “co-pay accumulator program” that – usually unknown to the patient – prevents manufacturer assistance coupons to co-pay to count for both the patient’s deductible and the maximum out-of-pocket expense. Unfortunately, the patient ends up paying more for the prescription drug, even though he needed financial assistance to pay for it in the first place. Patients can suffer financial hardship, especially when they need expensive drugs.

For example, a patient can take a pre-exposure prophylaxis (PreP) to prevent HIV named Descovy, which retails for $2,165.79. The drugmaker, Gilead, has a co-pay (voucher) assistance program that helps patients pay for their medications. However, if the patient’s insurance company uses a copayment accumulation program, the patient’s discounted copayment does not count toward the patient’s annual out-of-pocket maximums. Eventually, the patient will end up paying their entire deductible. Sanborn’s bill, LD 1783, would prevent double billing, which would protect Mainers from financial hardship and ruin when they need expensive prescription drugs.

My colleagues and I are working in other ways to ensure patients can access their prescription medications. Roeder’s bill, LD 1776, would allow pharmacists to dispense emergency supplies of medication to a patient when a prescription authorization is not available. As long as the pharmacist has a record of a previous prescription, he can dispense medication to the patient.

The bill would require insurance companies to cover emergency drug supplies. The bill would also give patients with chronic conditions, such as asthma, diabetes or heart disease, the peace of mind of being able to access their medications in an emergency.

On these issues, and more, my colleagues and I remain committed to helping Mainers live happy, healthy, and full lives. I know there is still a lot of work to be done to make health care affordable for everyone, but I also know that these two bills will ease the financial strain caused by high health care costs and uncertain access to medicines. on prescription.

If you have questions about healthcare and medications, please contact Consumers for Affordable Healthcare. Its consumer help line is 1-800-965-7476. If you ever need further assistance or would like to share your comments and thoughts with me, please contact me.

Anne Carney represents Senate District 29: Cape Elizabeth, South Portland and part of Scarborough. She can be reached at [email protected] or 207-287-1515.

” Previous

read more
Medical supplies

37 Ghanaian health facilities receive medical supplies from ADDRA

Adventist Development and Relief Agency (ADRA) International presented a number of personal protective equipment (PPE) and other medical supplies to thirty-seven (37) Adventist and non-Adventist health facilities to protect frontline health workers against contamination with the deadly COVID-19. 19.

The items worth US$500,000.00 were presented to institutions through Adventist Health Services (GAHS) at its headquarters at Kwadaso in Kumasi.

This is the fourth time ADRA has donated supplies to hospitals since 2020, when the pandemic hit Ghana.
Items from the latest shipment include patient gowns – 9600 pieces, N95 surgical masks – 33,120 pieces, face masks (ear loops) – 96,000 pieces
Speaking to the press after the presentation, Mr. John Schroer, director of Global Missions System Outreach of Adventist Health (worldwide), said his goal is to help build programs that will be sustainable over the long term. and not to provide few resources. .

Mr. Schroer commended Adventist Health Services Ghana for its incredible performance which influenced ADRA International’s decision to select Ghana as a recipient country.

ADRA Ghana Country Director Dr. William Y. Kpakpo Brown said the organization’s commitment is to support health workers in the fight against the spread of COVID-19.

“It is about showing support at this crucial time. This initiative also serves health workers, protecting them from contracting the deadly virus and improving the delivery of health care across the country,” he said. -he adds.

Dr Kpakpo Brown explained that since the lives of frontline health workers were crucial to the survival of the industry, the items would help minimize infections through body-to-body contact.

He gave assurances that ADRA will continue to support health workers to ensure they work in a safer environment to save lives.

Ghana Adventist Health Services (GAHS) Director, Pastor Dr. Paul Amoh Kyeremeh, who received the items on behalf of the 37 beneficiary institutions, expressed his gratitude to ADRA for this wonderful gesture.

He revealed that with the support of ADRA, GAHS was able to improve its services and expand some of its facilities and expressed the hope that GAHS would become a center of medical excellence in Ghana in a few years.

Dr Amoh emphasized that the war against COVID-19 could not be fought alone but required cross-sectoral collaboration for Ghana to win the war.

He expressed his delight at the praise from ADDRA International on the performance of Adventist health services in Ghana, and promised to lead GAHS to higher levels in health care delivery.
ADRA is the humanitarian wing of the Seventh-day Adventist Church. Since 1983, ADRA has partnered with governments, local communities and organizations to provide crisis relief and sustainable development interventions to improve lives.

read more
Medical products

Medical Products Stock Earnings Feb. 2: BSX, TMO and More

The last Revenue overview reflects a considerably strong quarterly performance for the Medical sector so far this reporting cycle. According to the sector scorecard, 8.9% of companies in the medical sector, constituting nearly 29.2% of the sector’s market capitalization, reported profits through January 26. Of these, 80% beat earnings estimates and 60% beat the same for revenue. Profits were up 27% year over year on revenue up 12.2%.

This dashboard reflects stability in the United States on continued economic reopening amid the resurgence of COVID-19 cases. However, supply chain disruptions are still significant, thanks to the emergence of the Omicron variant. Additionally, many parts of the COVID-affected international market are still suffering due to lower cash flow and tough economic conditions.

Overall, fourth-quarter profits for the medical sector are expected to rise 18.4% on a 12.2% increase in sales. That compares to reported earnings growth of 29.7% and revenue growth of 15.7% in the third quarter. It is worth mentioning that the medical sector is expected to be one of the seven sectors with the strongest earnings growth in the fourth quarter.

Quarterly summary of medical products

The dynamic nature of the COVID-19 crisis is rapidly transforming the landscape of the medical products industry. Medical products Corporate collective activities (within the broader medical sector) showed a sequential decline in terms of legacy core activity in the third quarter. So far, the fourth quarter reporting cycle has shown a sequential rebound in terms of the companies’ legacy core business despite the emergence of the new Omicron variant. This rebound can be attributed to the fiscal and monetary stimulus measures and the mass vaccination campaign at home and abroad. Although companies are seeing a sequential recovery in basic activity, the improvement in the overall trend is still below the pre-COVID level.

It should be mentioned here that disruptions in the form of the emergence of newer, more infectious variants of COVID-19 have again begun to delay non-COVID-19 elective hospital admissions and procedures. Meanwhile, with resurgences of COVID-19 and rising case numbers, manufacturers of tests, vaccines and therapeutics have witnessed massive market uptake of their products and support services. COVID-related health care in the fourth quarter.

Specifically, fourth-quarter diagnostic test inventory results have so far shown considerable growth, driven by an increase in demand for COVID-19 tests, which had seen a slowdown in demand in the third quarter, a report said. gained momentum in the fourth quarter, in line with industry trends.

Let’s take a look at four Medical Products players who are due to announce their results on February 2.

Boston Scientific Society BSX: In the fourth quarter, within the Urology/Pelvic Health division of Boston Scientific, sales of the Stone, Prostate Health and Pelvic Health franchises are expected to have recorded strong growth. The acquisition of Lumenis (closed in September) should have contributed a full quarter to the company’s sales. The LithoVue, SpaceOAR and Rezum product lines should have performed well. The company continues to expect urology/pelvic health to have one of the fastest potential recovery curves, aided by a higher in-office ASE mix for most elective procedures. (Read more: What do Boston Scientific’s fourth quarter results have in store for us?)

Zacks’ consensus estimate for fourth-quarter earnings per share is pegged at 44 cents and revenue at $3.10 billion.

Boston Scientific Corporation Award and EPS Surprise

Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote

Boston Scientific doesn’t have the right combination of the two key ingredients – a silver lining ESP Earnings and a Zacks Rank #3 (Hold) or better. BSX has an ESP on gains of 0.00% and carries a Zacks rank of #4 (sell). You can discover the best stocks to buy or sell before they’re flagged with our Income ESP filter.

You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Thermo Fisher Scientific Inc. TMO: Thermo Fisher’s Life-Science Solutions segment is expected to have seen strong revenue contributions driven by growing demand for COVID-19 testing with the emergence of the Omicron variant during the fourth quarter. Additionally, vaccine and therapeutics production supplies (recognized in the BioProduction and Biosciences businesses) are expected to have contributed strongly to the company’s growth in the fourth quarter. Thermo Fisher is expected to have seen robust growth in the areas of genetic sciences, biosciences and biomanufacturing thanks to the surge in economic activity globally and the company’s response to the pandemic. (Read more: Increase in COVID testing to boost Thermo Fisher Q4 revenue)

Zacks’ consensus estimate for its fourth-quarter earnings per share is set at $5.22. Revenue is expected to be $9.03 billion.

Thermo Fisher Scientific Inc. Prize and EPS Surprise

Thermo Fisher Scientific Inc. Prize and EPS Surprise

Thermo Fisher Scientific Inc. price-eps-surprise | Quote from Thermo Fisher Scientific Inc.

TMO has a +12.77% win ESP and a #3 Zacks rank.

Hologic, Inc. HOLX: Hologic’s diagnostics business likely experienced robust growth in the first quarter of fiscal 2022 due to increased demand for COVID-19 testing. With that in mind, in November 2021, the company confirmed that its three SARS-CoV-2 tests detect the recently emerged Omicron variant of the coronavirus. This development should have boosted Hologic’s diagnostics revenue in the first fiscal quarter. The same month, Hologic launched the Novodiag system for on-demand molecular testing in Europe. This should have witnessed strong market uptake in the fiscal first quarter as it capitalized on the surge in coronavirus cases induced by the Omicron variant, thus adding to revenue. (Read more: Hologic to Report First Quarter Results: What’s in the Cards?)

Zacks’ consensus estimate for its first-quarter earnings per share is set at $1.21. Revenue is expected to be $1.12 billion.

Hologic, Inc. Price and EPS Surprise

Hologic, Inc. Price and EPS Surprise

Hologic, Inc. price-eps-surprise | Hologic, Inc. Quote

The company has an ESP on Earnings of -1.65% and a #2 Zacks Rank (Buy).

McKesson Corporation MCK: The company’s US pharmaceutical and specialty solutions segment likely acted as a key growth driver in the third quarter of fiscal 2022. The segment should have benefited from market growth and higher volumes of specialties during the quarter to appear. However, brand-to-generic conversions may have weighed on segment performance. The growing demand for COVID-19 testing (due to the resurgence of COVID-19) and improved primary care patient visits have likely positively impacted the company’s medical-surgical solutions segment. (Read more: McKesson to Report Third Quarter Results: What’s in the Cards?).

Zacks’ consensus estimate for its third-quarter earnings per share is set at $5.38. Revenue is expected to be $66.13 billion.

McKesson Corporation and EPS Surprise Award

McKesson Corporation and EPS Surprise Award

McKesson Corporation price-eps-surprise | Quote from McKesson Corporation

MCK has a +1.86% earnings ESP and a #3 Zacks rank.

Stay up to date with upcoming results announcements with the Zacks Earnings Schedule.

7 best stocks for the next 30 days

Just Released: Experts distill 7 elite stocks from the current Zacks No. 1 Ranking 220 Strong Buys list. They consider these tickers “most likely for early price increases.”

Since 1988, the full list has beaten the market more than 2 times with an average gain of +25.3% per year. So be sure to give your immediate attention to these 7 handpicked ones.

Discover them now >>

Click to get this free report

Boston Scientific Corporation (BSX): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Inventory Analysis Report

McKesson Corporation (MCK): Free Stock Analysis Report

Hologic, Inc. (HOLX): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

read more
Medical products

These Are The Top 10 Competitive Medical Products And Equipment…

(MENAFN-ValueWalk) Bru-nO / Pixabay

The medical products and equipment industry has experienced remarkable growth over the past decade. This industry consists of businesses that sell instruments, devices, or machines used in the prevention, diagnosis, or treatment of disease or ailment. The medical products and equipment industry, in turn, depends on many other industries to maintain its competitive edge, including telecommunications, software development, biotechnology and more. Let’s take a look at the top ten medical product and equipment companies.

Get the complete Henry Singleton series in PDF

Get the complete 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email it to co-workers

Q4 2021 Hedge Fund Letters, Talks & More

This fund focused on the financial sector has performed well in 2021

The Arbiter Global Financials fund generated an estimated return of 26%, compared to its benchmark, the MSCI ACWI Financials Index, which generated a return of 25.1%. In their year-end letter, which was obtained by ValueWalk, Arbiter’s Matthew Hankin and Ross Levin said they believe their portfolio is well positioned in the current environment. Q4 2021 Hedge Fund Letters, Conferences and Read More

Contents Pin up

  • 1. Ten largest medical products and equipment companies

  • 2. Dentsply Sirona (>$4 billion)

  • 3. Edwards Lifesciences (>$4.3 billion)

  • 4. Intuitive surgery (>$4.4 billion)

  • 5. Zimmer Biomet Holdings (>$7.9 billion)

  • 6. Boston Scientific (>$10.7 billion)

  • 7. Baxter International (>$11.3 billion)

  • 8. Stryker (>$14.8 billion)

  • 9. Becton Dickinson & Co. (>$17.2 billion)

  • 10. Danaher (>$20.5 billion)

  • 11. Abbott Laboratories (>$31.9 billion)

Ten largest medical products and equipment companies

We used the latest disposable income figures to rank the ten largest medical products and equipment companies. We only used Fortune 1000 companies for our list. Here are the ten largest medical products and equipment companies:

  • Dentsply Sirona (>$4 billion)
  • Founded in 1899 and based in Charlotte, North Carolina, this company designs, manufactures, sells and distributes professional dental products and technologies. Dentsply (NASDAQ: XRAY) has the following business segments: Technologies and Equipment and Consumables. Its shares are down more than 8% in the last three months and more than 6% in the last month. Dentsply Sirona reported a net loss of over $80 million in 2021 and a net profit of over $260 million in 2020.

  • Edwards Lifesciences (>$4.3 billion)
  • Founded in 1958 and based in Irvine, Calif., this company is dedicated to patient-focused medical innovations related to critical care monitoring and heart disease. Edwards Lifesciences Corp (NYSE: EW) products are classified into three categories: surgical structural heart, critical care and transcatheter heart valves. Its shares are down more than 9% in the last three months and more than 18% in the last month. Edwards Lifesciences reported net income of over $1.5 billion in 2021 and over $800 million in 2020.

  • Intuitive surgery (>$4.4 billion)
  • Founded in 1995 and based in Sunnyvale, California, this company develops, manufactures and markets da Vinci Surgical Systems and related instruments and accessories for invasive surgery. Intuitive Surgical, Inc. (NASDAQ: ISRG) products include da Vinci and Ion. Its shares are down more than 23% in the last three months and more than 24% in the last month. Intuitive Surgical reported net income of over $1.7 billion in 2021 and over $1 billion in 2020.

  • Zimmer Biomet Holdings (>$7.9 billion)
  • Founded in 1927 and based in Warsaw, Indiana, this company offers musculoskeletal health services. Zimmer Biomet Holdings Inc (NYSE: ZBH) has the following geographic segments: Americas and Global, EMEA and Asia Pacific. Its shares are down more than 17% in the last three months and more than 6% in the last month. Zimmer Biomet Holdings reported a net loss of over $130 million in 2021 and a net profit of over $1.10 billion in 2020.

  • Boston Scientific (>$10.7 billion)
  • Founded in 1979 and based in Marlborough, Mass., this company is an innovator of medical solutions that help improve patient health. Boston Scientific Corporation (NYSE: BSX) has the following business segments: Rhythm and Neuro, Cardiovascular and MedSurg. Its shares are down nearly 1% in the past three months, but up nearly 19% in the past year. Boston Scientific announced a net loss of more than $80 million in 2021 and a net profit of more than $4.70 billion in 2020.

  • Baxter International (>$11.3 billion)
  • Founded in 1931 and based in Deerfield, Illinois, this company markets kidney and hospital essential products, such as sterile intravenous solutions, infusion systems and devices, acute and chronic dialysis, etc. Shares of Baxter International Inc (NYSE: BAX) are up nearly 7% in the past three months, but down nearly 2% in the past month. Baxter International reported net income of over $1 billion in 2021.

  • Stryker (>$14.8 billion)
  • Founded in 1941 and based in Kalamazoo, Michigan, this company deals in technology products and services. Stryker Corporation (NYSE: SYK) has the following business segments: Orthopedics, MedSurg and Neurotechnology & Spine. Its shares are down more than 7% in the past three months. Stryker reported net income of over $1.90 billion in 2021 and over $1.50 billion in 2020.

  • Becton Dickinson & Co. (>$17.2 billion)
  • Founded in 1897 and based in Franklin Lakes, NJ, this company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Becton Dickinson and Co (NYSE: BDX) has the following business segments: BD Medical, BD Life Sciences and BD Interventional. Its shares are up more than 5% in the past three months and nearly 1% in the past month. Becton Dickinson reported net income of over $2 billion in 2021 and over $800 million in 2020.

  • Danaher (>$20.5 billion)
  • Founded in 1969 and based in Washington, DC, this company designs, manufactures and markets medical, commercial, professional and industrial products and services. Danaher Corporation (NYSE: DHR) has the following business segments: life sciences, environmental and applied diagnostics and solutions. Its shares are down more than 9% in the past three months and nearly 11% in the past month. Danaher reported net income of over $6.30 billion in 2021 and over $3.60 billion in 2020.

  • Abbott Laboratories (>$31.9 billion)
  • Founded in 1888 and based in Abbott Park, Illinois, this company discovers, develops, manufactures and sells a line of health care products. Abbott Laboratories (NYSE:ABT) includes the following business segments: diagnostics, medical devices, established pharmaceuticals and nutritional products. Its shares are down nearly 3% in the past three months and nearly 10% in the past month. Abbott reported net income of over $7 billion in 2021 and over $4.40 billion in 2020.

    Updated January 31, 2022 at 10:22 a.m.

    MENAFN31012022005205011743ID1103620332


    Legal disclaimer: MENAFN provides the information “as is” without warranty of any kind. We assume no responsibility for the accuracy, content, images, videos, licensing, completeness, legality or reliability of any information in this article. If you have any complaints or copyright issues related to this article, please contact the provider above.

    read more
    Medical supplies

    Better Health brings medical supplies to patients’ homes

    The workplace isn’t the only thing building a permanent presence in our homes in the wake of the pandemic – health also finds its place in our personal spaces.

    After years of working in healthcare, Naama Stauber Beckler realized that the existing system was failing some people, especially those dealing with health issues that required home supplies. So she set out to found Better Health, a direct-to-consumer service provider that delivers medical supplies directly to patients’ doors.

    “I have identified a gap in the market for people with chronic conditions who need to use [medical devices at home]says Stauber Breckler of the operation, which she launched in 2019. ideal product for you, learning how to use them and integration into your life is really broken.

    Read more: Long story short: get ready for big changes in healthcare this year

    Traditionally, sending medical products home with patients from hospitals was a lengthy process – it started with a doctor’s referral, then required a lot of work on the patient’s part to find suppliers who would transport the product. Then they had to connect distributors and doctors, contact the insurers themselves, and finally, go out and collect their supplies.

    With Better Health, medical supplies, such as catheters and colostomy bags, are delivered directly to patients once approved by doctors and distributors, and comes with telehealth tools including education and peer support.

    More than 4.5 million people receive home health care and relying on businesses to provide and maintain their oxygen machines, wheelchairs, hospital beds, prosthetics and other durable home medical equipment, according to the CDC. And between 725,000 and one million people in the United States currently live with a stoma (a surgical opening to help waste material leave the body), according to the United Ostomy Associations of America. It is estimated that 100 million urinary catheters are sold worldwide each year.

    Read more: As long as employers control employee healthcare, life-saving technologies will be underutilized

    Before the pandemic, the the traditional method left a lot of room for error, says Stauber Beckler, noting that patients often had to travel to the hospital just to get needed supplies. COVID-19, of course, amplified the problem: as access to hospitals and doctors dwindled, patients with chronic illnesses at home found themselves looking for solutions.

    “What we’ve really seen over the last two years, and especially during the pandemic, is how far telehealth has evolved,” says Stauber Beckler, noting that using telehealth to educate patients is not will not only make life easier for consumers, but also alleviate unnecessary stress and demand on hospitals. “By serving underserved, perhaps smaller-volume populations — like those enrolled in Medicaid, the LGBTQ community, women — we’re already seeing better solutions emerge for them.”

    read more
    Medical supplies

    Personal perspective: How to strengthen the supply chain of essential medical supplies and medicines

    As the COVID-19 pandemic spread across the country, governments and the private sector tore through their stockpiles of personal protective equipment (PPE) and other resources. Several supply chain issues quickly emerged, including lack of visibility into sources of supply, a fragmented approach to ordering and fulfillment, and an overreliance on offshore manufacturing.

    While we have made progress in managing aspects of the pandemic, disruptions to the supply chain, including raw materials, manufacturing, shipping, distribution and “last mile” delivery remain. in a system that is not designed for the demands of a pandemic.

    With a few targeted strategies, it is possible to reverse these disturbances. For its part, Premier, a health care improvement company uniting 4,400 American hospitals and health systems and partner of the CHAMPS Purchasing group based in northeast Ohio, is concerned with the risk management of the supply chain for years, and we have developed forward-thinking capabilities. to help protect against interference.

    To strengthen the supply chain, Premier and CHAMPS are calling for the implementation of key national priorities to meet the growing demand for essential medical supplies and medicines. We need to take a broader approach to creating an end-to-end supply chain that is transparent, diverse and reliable. Beyond quantities, we must also ensure that the United States has established contractual relationships that include contingency plans to increase production as soon as future needs are identified.

    Specifically, we need to address the following points.

    • The need for domestic manufacturing: The pandemic has underscored the need for better local access to essential medical supplies, which is why we are advocating for a short-term tax incentive of 30% to support domestic manufacturing. We also believe that the private sector can play a role in promoting change related to the manufacturing of essential goods.

    In March 2020, Premier launched a unionized model to ensure a robust and resilient supply chain for essential medical products. The program provides a vehicle through which Premier and its members pool capital to invest in domestic manufacturers who can supply products in short supply, providing initial cash needed to expand production capacity and modernize the plant, as well as long-term purchasing commitments to incentivize innovation. This ensures that providers have a cost-effective national alternative for their patient care needs. Here in Northeast Ohio, CHAMPS Group Purchasing has partnered with JobsOhio to implement agreements with suppliers of PPE and related products as part of our commitment to supporting local national suppliers, diversified and small businesses to advance the region’s economy.

    • The need for an innovative global sourcing strategy: Past situations such as H1N1, Ebola, and Hurricane Maria have highlighted the vulnerabilities associated with over-reliance on a single country for medical supplies and medicines. In response, several organizations (including ours) have diversified PPE production, expanding operations to multiple countries and regions to mitigate ongoing risks of product shortages. As part of this, we must also ensure that suppliers have a say in determining what should be included in the national strategic stock of equipment.
    • Tech-enabling supply chain: Until recently, hospitals were alone in translating local outbreaks of COVID-19 into immediately meaningful information regarding capacity and supplies. Now, providers are using technology to be better informed about how quickly cases are spreading and what supplies they need at any given time. This new technology takes advantage of real-time monitoring capabilities, providing early warnings, predicting surges and helping organizations plan coordinated responses where they are needed most.

    Additionally, the federal government needs technology that will provide visibility into what supplies are in inventory, distribution, and hospital inventories during national emergencies. This will allow allocation to places in need and reduce hoarding and the illicit market, issues that have challenged America during the first nine months of the pandemic.

    When healthcare providers can predict COVID-19-related hospitalizations and have confidence in the sufficiency of supplies of essential commodities, this creates a positive ripple effect – relieving pressure on supply chains, ensuring more responsive care in communities and helping to keep businesses and schools open and running.

    Even as COVID-19 has exposed supply chain flaws and transformed the healthcare landscape, together we continue to show and improve to meet the challenges posed by the pandemic and drive healthcare innovation. health for the future.

    We must come together to ensure access to the supplies, data, analysis and intelligence needed to survive and thrive in a challenging environment.

    Lane is President and CEO of the Center for Health Affairs and CHAMPS Healthcare. Alkire is President and CEO of Premier Inc.

    read more
    Prescription drugs

    Iran’s Medicine Mafia Behind Shortages and High Cost of Prescription Drugs – OpEd – Eurasia Review

    A short prelude

    Since the birth of the tyrannical regime of the mullahs in Iran, another social and frightening phenomenon has also been born; widespread monopolization. After the 1979 anti-monarchy revolution in Iran and the establishment of the religious dictatorship, the regime’s power vultures began to dominate and take control of the main outlets of the economy. The creation of a multitude of false and non-existent legal and illegal entities, holdings, bank accounts and businesses has been the evil product of this domination and control.

    After the passage of more than four decades, the Iranian economy is recognized by its two distinct fronts. On the one hand, the regime, its repressive forces and its affiliates, and on the other, the Iranian people.

    The first front is dominated by the office of Iran’s Supreme Leader Khamenei, which has around $200 billion in assets, the infamous Islamic Revolutionary Guard Corps (IRGC) and a host of other entities sharing the same ideas.

    The second front is made up of ordinary Iranian citizens who, according to Speaker of Parliament Ghalibaf, make up around 94% of the population.

    The current state of prescription drugs in Iran

    The availability and affordability of prescription drugs in Iran fell sharply more than two years ago, and it has become almost impossible to find foreign drugs after the recent pandemic. According to media reports, ordinary Iranians are experiencing a severe shortage of prescription drugs and drug prices are skyrocketing across the country.

    Many people complain that pharmacies are unable to supply their prescriptions. As expected, government officials are offering conflicting reasons — including US sanctions — for shortages and price hikes; however, pharmacists blame government mismanagement of health care, corruption, the black market and the collapse of Iran’s currency.

    In September 2018, it was reported that the price of drugs prescribed to dialysis and kidney transplant patients had increased by 100-300% since March of the same year. Other prescription drugs have also seen unprecedented price increases. Many senior officials in the governments of former President Hassan Rouhani and current President Ebrahim Raisi have blamed current drug shortages on US-imposed economic sanctions. Yet the US Treasury Department’s list does not include drugs.

    The source of the problem

    The real reason for the shortage of prescription drugs lies in the Iranian regime’s corrupt system and its dominance over the pharmaceutical industry.

    The Iranian medical mafia is not a new phenomenon; with the onset of the COVID-19 pandemic in Iran in 2019, people had to go through a winding path of illegal channels and contacts, called the Iranian medicine mafia, instead of pharmacies, to obtain prescription drugs, often paying much more than the advertised price. Looking back, one might realize that Iran’s medical mafia had been around for many years, but the spread of COVID-19 helped it gain strength and expansion.

    Regarding the shortage of certain items in pharmacies, Ali Fatemi, Vice President of the Iranian Pharmacists Association, said: “Previously, the shortage of medicines was related to foreign medicines and medicines for certain diseases, but now we have problems in supplying certain Iranian medicines and this shortage in our country is unprecedented”.

    Iran’s new budget and prescription drugs

    To raise funds for its budget deficit, the government of Ebrahim Raisi plans to eliminate all pre-existing subsidies for prescription drugs. Facing public anger and widespread criticism from the regime’s own analysts and politicians, government officials say prescription drugs will still be subsidized because they fall under the subsidized exchange rate category.

    However, leaders of drug importing companies insist that the prescription subsidies allocated in the budget are not enough to meet the need. The Director General for Pharmaceutical Affairs confirmed concerns raised by pharmaceutical companies about subsidies and their availability.

    Iranians are angered by reports of drug trafficking and the sale of drugs on the black market, which is owned and controlled by regime elites. This is when the authorities claim to have enough funds to import certain drugs; drugs that cannot be found in pharmacies and that end up on the black market at exorbitant prices.

    In a report published in January, Colonel Davoud Moazami Goudarzi, head of Tehran’s cyberpolice, said an Instagram page with more than 90,000 followers was selling drugs in cyberspace. The report says more than 500,000 rare drugs were confiscated from the site.

    In conclusion

    It is safe to say that in principle there are enough drugs in the country, but the Iranian medical mafia, i.e. the regime elites and the IRGC, are selling the drugs to desperate patients. through the black market to earn more money. Most Iranians cannot afford to buy drugs on the black market, which has led and may lead to more deaths and poverty

    read more
    Medical supplies

    Dwindling medical supplies in northern Ethiopia prevent health workers from helping those in need – Ethiopia

    As the conflict in northern Ethiopia continues to evolve, hundreds of thousands of people have been displaced, straining the region’s health system and medical personnel.

    The ICRC is deeply concerned about the availability of medical care, including medicines and medical equipment. Health services lack essential medical supplies and, in some cases, infrastructure has been severely damaged. This makes access to health care very difficult, depriving people of the essentials they need to survive.

    The ICRC is adapting its assistance efforts by focusing on the most vulnerable. However, our ability to respond has become limited as medical supplies dwindle, with the delivery of humanitarian aid severely hampered by a combination of fighting, insecurity and access constraints.

    “Some hospitals in Amhara have closed for lack of medicines,” said Micha Wedekind, the ICRC’s response officer in Amhara and Afar. “People with chronic diseases die every day and women give birth at home because health facilities are not functional and often without electricity or water.”

    “In Tigray, single-use items such as gloves, surgical equipment and even chest tubes are washed and reused, increasing the risk of infections. In some places, doctors have replaced disinfectant with salt to clean the wounds,” said Apollo Barasa, health coordinator at the ICRC delegation in Ethiopia. “Patients are receiving expired drugs, oxygen plants are no longer working and some health facilities cannot provide routine vaccines.

    The ICRC reminds all parties to the conflict that they must facilitate the delivery of humanitarian aid without delay to those most in need.

    Our medical support this month has included seven healthcare facilities around Dessie, including Hayk, Mersa, Woldiya and Kobo. Throughout 2021, with the Ethiopian Red Cross, the ICRC supported 130 health facilities in the Amhara, Afar, Tigray, Oromia and Somali regions. More than 110,000 people have benefited from our medical programs and 9,800 people have received physiotherapy and mobility care.

    Beyond medical assistance, the ICRC continues to be concerned about the food and livelihood situation in northern Ethiopia. Last week, our teams were able to bring humanitarian aid to communities in Lalibela, Amhara, for the first time in six months, providing 2,500 people with food and 6,000 people with household items such as mattresses, jerry cans , cooking utensils and solar lamps. In Mekelle, the ICRC distributed essential household and hygiene items to more than 900 displaced people.

    Finally, while continuing our operations in the region, the ICRC is deeply concerned by recent reports of continued fighting in northern Ethiopia, resulting in civilian casualties, including in recent airstrikes.

    We call on all parties to the conflict to respect the rules and obligations of international humanitarian law, which provide that civilians are protected from attack and that everything possible must be done to verify that targets are military objectives. Where possible, civilians should also be kept away from the vicinity of military objectives.

    In 2021, the ICRC has:

    – Assisted 655,000 people with household supplies, shelter and cash across the country, with a focus on northern Ethiopia
    – provided 875,000 people with agricultural and livestock assistance
    – Facilitated access to drinking water and sanitation for 1,950,000 people, including in places of detention
    – Helped over 169,000 people restore or maintain family ties, facilitating the exchange of news between family members.

    For more information, please contact:

    Fatima Sator, ICRC Addis Ababa, [email protected] Mr. +251944101700
    Alyona Synenko, ICRC Nairobi, [email protected] Mr. +254716897265

    read more
    Medical products

    2022 Emergency Oxygen Kits Market Analysis by Major Key Players

    New Jersey, United States,-

    A new report titled “(Emergency Oxygen Kits Market)” by Market Research Intellect sheds light on the industry dynamics and current and future trends that play a key role in determining the expansion of the market. ‘business. The report also highlights the key driving factors and restraints affecting the growth. For a comprehensive understanding, experts reviewed regulatory scenarios, market entry strategies, industry best practices, pricing strategies, technology and consumer environment, sales and demand outlook . It also included growth estimates to provide users with accurate statistics and facts. The report will provide readers with a broader and more transparent picture of the overall scenario.

    Corona impact outlook 19

    This section of the report shows the impact of the global Corona outbreak on businesses. The report describes the impact on manufacturing activity, production, demand, supply chain, logistics management and distribution networks. The analysts have highlighted the measures or strategies taken by the company to combat the impact of Corona 19. In addition, they have identified a major opportunity to emerge after Corona 19. This will help players take advantage of the opportunity to recover losses and stabilize the activity.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=559836

    Additionally, market revenue based on region and country is provided in the Emergency Oxygen Kits report. The authors of the report also shed light on common business tactics adopted by players. Key players of the global Emergency Oxygen Kits market and their comprehensive profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Emergency Oxygen Kits market are mapped by the report. Using this report, key players in the global Emergency Oxygen Kits Market will be able to make sound decisions and plan their strategies accordingly to stay ahead.

    The competitive landscape is an essential aspect that every key player must know. The report highlights the competitive scenario of the Global Emergency Oxygen Kits Market to know the competition at country and global level. Market experts have also provided an outline of each major player in the global Emergency Oxygen Kits market, considering key aspects such as business areas, production, and product portfolio. Additionally, the companies in the report are studied based on key factors such as company size, market share, market growth, revenue, production volume, and profit.

    Major Players Covered by Emergency Oxygen Kits Markets:

    • Mada Medical Products
    • Inc.
    • Marine Medical Antibes
    • Corporate Life
    • FERNO
    • Allied Health Care
    • Mega medical

    Emergency Oxygen Kits Market Split By Type:

    Emergency Oxygen Kits Market Split By Application:

    • Hospitals and Clinics
    • Industrial and factories
    • Public facilities

    The Emergency Oxygen Kits Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the Global Emergency Oxygen Kits Market in the coming years. This segmental analysis will surely prove to be a helpful tool for readers, stakeholders, and market players to get a complete picture of the global Emergency Oxygen Kits market and its growth potential in the years future.

    Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=559836

    Scope of the Emergency Oxygen Kits Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in USD Million and CAGR from 2021 to 2027
    Segments Covered Types, applications, end users, and more.
    Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
    Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

    Regional Analysis of the Emergency Oxygen Kits Market can be represented as follows:

    Each regional Emergency Oxygen Kits industry is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

    Based on geography, the global emergency oxygen kit market has been segmented as follows:

      • North America includes the United States, Canada and Mexico
      • Europe includes Germany, France, UK, Italy, Spain
      • South America includes Colombia, Argentina, Nigeria and Chile
      • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

    Answers to key questions in the report:

    • What is the growth potential of the Emergency Oxygen Kits markets?
    • Which product segment will take the lion’s share?
    • Which regional market will impose itself as a precursor in the years to come?
    • Which application segment will grow at a rapid pace?
    • What are the growth opportunities that may emerge in the Lock Washers industry in the coming years?
    • What are the major challenges that the global emergency oxygen kit markets may face in the future?
    • Who are the leading companies in the Global Emergency Oxygen Kits Market?
    • What are the key trends that are positively impacting market growth?
    • What are the growth strategies considered by the players to maintain their hold in the global emergency oxygen kits market?

    For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-emergency-oxygen-kits-market-size-forecast/

    The study thoroughly explores the profiles of major market players and their major financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the Emergency Oxygen Kits market production, revenue, market share and growth rate for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical failure data of emergency oxygen kits from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intellect

    Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. customers, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    USA: +1 (650)-781-4080
    UK: +44 (753)-715-0008
    APAC: +61 (488)-85-9400
    US toll free: +1 (800)-782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Medical supplies

    Life for Relief and Development (LIFE) provides millions of medical supplies worldwide

    Image captured from an ambulance donated by LIFE in Bangladesh

    Image captured of medical supplies distributed in Sierra Leone

    LIFE is providing nearly $10 million worth of medical supplies during 2021 to eight different countries around the world

    SOUTHFIELD, MICHIGAN, USA, January 13, 2022 /EINPresswire.com/ — Many countries around the world lack essential health care and the COVID-19 pandemic has only made these situations worse. To help fill this shortage, Life for Relief and Development (LIFE) sent a total of 21 shipments to eight different countries around the world, totaling almost $10 million during 2021. Countries such as Somalia, Somaliland, Lebanon, Mali, Senegal, Sierra Leone , Pakistan and Ghana have all benefited from these remittances. Medical supplies included a variety of items, as needed, such as PPE, respiratory supplies, surgical equipment, wheelchairs, walkers, crutches, oxygen concentrators and more. Ambulances were also donated to Lebanon and Bangladesh to improve transport to health facilities.

    “The helping hand you extended and your generous donation of medical supplies and medical equipment have been well received and will go to our general hospital to continue serving our community. Thank you once again for your kind and generous support and we look forward to maintaining a liaison with you,” said Sister Nicolas Akiki, Director of Wardieh Hospital – Rosary Sisters Hospital in Lebanon.

    LIFE is constantly striving to get medical supplies to the countries that need them most, and at times like these, many countries are in dire need of help.

    “Health care is a right, not a privilege, and we make it our priority at LIFE to be able to provide it to those in need around the world, giving hope to those who may not see not the light at the end of a very dark time. After all, where there is LIFE, there is hope,” said Dr. Hany Saqr, CEO of LIFE.

    Life for Relief and Development is a global relief and development organization, headquartered in Southfield, Michigan, USA. Life is dedicated to providing humanitarian aid to people regardless of race, gender, religion and cultural background. As a registered 501(c)(3) nonprofit organization, Life has consultative status with the United Nations Economic and Social Council. He is also a member of InterAction, the largest alliance of US-based NGOs and partners of humanitarian agencies such as UNICEF, Brothers Brother Foundation and World Medical Relief. Over the past 29 years, LIFE has distributed more than $520 million in humanitarian and relief aid to more than 46 countries. Life works diligently to help the poor and needy in a number of countries such as: Afghanistan, Ghana, Haiti, Iraq, Jordan, Lebanon, Pakistan, Palestine (through our office in Israel), Sierra Leone, Syria and the United States as well. like other countries. When natural disasters strike, LIFE rushes in to answer the call for help and provide basic humanitarian aid.

    Hala M Sanyurah
    +1 330-815-4706
    [email protected]
    Life for relief and development
    Visit us on social media:
    Facebook
    Twitter
    Other

    read more
    Generic drugs

    Oncohiv to Restore Confidence in Generic Drugs with Safe and Reliable Generic Options

    India is also a country with one of the highest direct spending per capita

    In a developing country like India, generic drugs play a vital role in supporting the public health system. Similar to brand names, these generic drugs also need FDA approval stating that the drug composition, dosage, and kinetics are the same as brand name drugs. However, generic drugs are generally 30-80% cheaper than their brand-name equivalents, making them more cost effective for the general population. Oncohiv, a distributor of generic and over-the-counter drugs, offers on its online platform some of the best generic drug options for a wide range of conditions.

    India is home to a large portion of the poor population who cannot access modern health facilities due to its prohibitive cost. India is also a country with one of the highest direct spending per capita. Thus, generic drugs can significantly reduce the costs of medical services and make public health care more affordable. At the same time, it is also proven that generic drugs are no different from their branded counterparts in terms of dosage, route of administration, strength, quality, kinetics and intended use. Given its merit to the public health system, the Indian government has taken several regulatory steps to popularize the use of generics in India. In 2008, the Indian government, through the Department of Pharmaceuticals, launched a new “Jan Aushadhi” initiative as part of this effort. The Medical Council of India has recommended that every doctor prescribe drugs with legible generic names and that he or she ensure that there is a rational prescription that promotes the use of generic drugs. Oncohiv’s online generic medicine platform aligns with the same vision of affordable and accessible healthcare in India.

    Oncohiv offers a wide variety of cancer drugs that treat a myriad of cancers and health risks, including blood cancer, brain cancer, breast cancer, liver cancer, leukemia, low platelet count, l hepatic encephalopathy, prostate cancer, skin cancer, psoriasis and thyroid cancer. They are also certified distributors of drugs used in the treatment of diseases such as hepatitis B, hepatitis C, Hodgkin’s disease and HIV / AIDS. Following the latest coronavirus outbreak, they listed generic ivermectin drugs used in the treatment of Covid19 like Iverheal 12, Iverheal 3, Iverheal 6, Iversun 12mg and Iverwon 12mg among many others to help people to easily obtain these emergency drugs. Ivermectin is a fast-acting drug that has been shown to be effective in curing several parasitic infections. In addition to treating the condition, the drug also lowers the risk of developing deadly foods.

    Oncohiv also offers life-saving medicines like Flacigo, hydroxychloroquine and doxycycline, as well as other antibiotic medicines.

    Oncohiv is a generics market that prioritizes compliance with strict regulatory measures to match international standards. A quality audit team works regularly to monitor all drugs and orders to ensure the best services and experiences for all their consumers. They carefully follow guidelines to ensure customer safety and privacy. Indeed, the products and brands offered by Oncohiv are manufactured in facilities approved by the World Health Organization (WHO) attesting to the safety of their drugs. In the post-pandemic world, when the government tries to rebuild its medical infrastructure, Oncohiv plans to help the government’s efforts with its generic and OTC products.

    End of

    read more
    Generic drugs

    Oncohiv will restore trust in generic drugs with safe and reliable generic options

    In a developing country like India, generic drugs play a vital role in supporting the public healthcare system. Similar to brand names, these generic drugs also need to get FDA approval stating that the composition, administration dosage, and kinetics of the drug are the same as the brand name drugs. However, generic drugs are typically 30-80% less expensive than their originator equivalents, making them more cost-effective for the general population. Oncohiv, a generic and over-the-counter drug distributor, offers some of the industry’s best generic drug options for a wide range of conditions on its online platform.

    India is home to a large portion of the poor population who lack access to modern healthcare facilities due to their prohibitive cost. India is also a country with one of the highest personal expenditure per capita. Thus, generic drugs can significantly reduce the costs of medical services and make public health care more affordable. At the same time, generic drugs are also proven to be no different from their branded counterparts in terms of dosage, route of administration, strength, quality, kinetics, and intended use. Considering its interest in the public healthcare system, the Indian government has taken several regulatory measures to popularize the use of generics in India. In 2008, the Government of India, through the Department of Pharmaceuticals, launched a new “Jan Aushadhi” initiative as part of this effort. The Medical Council of India has recommended that every doctor should prescribe drugs legibly with generic names and ensure that there is rational prescribing which promotes the use of generic drugs. Oncohiv’s online generic drug platform aligns with the same vision of affordable and accessible healthcare in India.

    Oncohiv offers a wide variety of cancer drugs treating a myriad of cancers and associated health risks, including blood cancer, brain cancer, breast cancer, liver cancer, leukemia, low platelet count, hepatic encephalopathy, prostate cancer, skin cancer, psoriasis and thyroid cancer. They are also certified distributors of drugs used in the treatment of diseases such as hepatitis B, hepatitis C, Hodgkin’s disease and HIV/AIDS. Following the latest coronavirus outbreak they have listed generic ivermectin drugs used in Covid19 treatment as Iverheal 12, Iverheal 3, Iverheal 6, Iversun 12mg and Iverwon 12mg among many others to help people easy access to these emergency drugs. Ivermectin is a fast-acting drug that has been proven to effectively cure several parasitic infections. In addition to treating the disease, the drug also reduces the risk of developing deadly foods.

    Oncohiv also sells lifesaving drugs like Flacigo, Hydroxychloroquine and Doxycycline along with other antibiotic drugs.

    Oncohiv is a generic marketplace that prioritizes compliance with strict regulatory measures to match international standards. A quality audit team works regularly to monitor all medications and orders to ensure the best services and experiences for all of their consumers. They carefully follow guidelines to ensure customer safety and privacy. Indeed, the products and brands offered by Oncohiv are manufactured in facilities approved by the World Health Organization (WHO) attesting to the safety of their medicines. In the post-pandemic world, as the government attempts to rebuild its medical infrastructure, Oncohiv plans to aid the government’s efforts with its generic and over-the-counter products.

    read more
    Medical products

    FDA Cleared Booster Dose for Teens – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

    United States: FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review

    To print this article, simply register or connect to Mondaq.com.

    During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

    • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
    • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
    • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
    • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
    • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
    • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
    • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
    • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

    The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

    POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

    Alston and Birds Health Care Week in Review, December 17, 2021

    Alston & Bird

    Below is Alston & Bird’s Healthcare Week review, which provides a summary of the latest healthcare regulatory news, advice and guidance; federal legislation and the work of congressional committees; reports, studies and analyzes; and other health policy news.

    read more
    Medical supplies

    Good Health Will connects medical supplies with those in need – Loveland Reporter-Herald

    Renee Juelfs, who works at the Good Health Will store in Loveland, says she has a rewarding job helping people with medical needs.

    “I have never had so much fun. I can’t call it work, ”she said recently.

    But for people with medical needs, Good Health Will is serious business.

    The 501 (c) 3 nonprofit, which has stores in Loveland and Greeley, receives donations of medical supplies and equipment and sells them cheaply to those in need.

    The process begins with the members of the community.

    Juelfs said that when people no longer need the medical equipment they bought, they often want to find someone else who can benefit from it.

    “They hate throwing this wheelchair away,” she said. “They want him to go to someone who needs him.”

    Prices may depend on the item and its use. A walker can cost $ 10. A hospital bed can cost $ 200.

    For large items, staff can look up the list price and divide it by four, or by two if it’s brand new, out of the box.

    Juelfs said that in her six years with Good Health Will, she has seen most clients learn of the nonprofit’s existence either through friends through word-of-mouth or by their doctor’s office.

    Sometimes people call from the emergency room to ask if there are black boots available. And sometimes when they have surgery planned, they get a list of the items they’ll need while recovering and come pick them up, Juelfs said.

    About 50% of customers who entered the Loveland store in the past month were new to the nonprofit, she said.

    Juelfs said the store also maintains an onward payment fund and staff can offer additional discounts if someone can’t afford what they need.

    The association helps fill a need of people facing short or long term medical needs and their associated costs, which it can only do with donations from the community.

    “There are more and more donations,” Juelfs said.

    Katie Diel, deputy director of Good Health Will, answered the following questions for The Reporter-Herald.

    1) What services do you offer in northern Colorado?

    Good Health Will is a local 501 (c) 3 organization that collects donated medical equipment and health care supplies and offers low cost purchase options for these items to the public at our two retail stores in Loveland and Greeley.

    Everyone is welcome to visit our stores from 9 a.m. to 5 p.m. Monday to Friday to donate and / or purchase items. Additionally, we provide pickup and delivery options for bulky and hard-to-move items.

    2) Have you seen the needs change during the pandemic, or have the needs changed over the years of activity?

    The need for affordable medical equipment and health care supplies has remained constant over the years and even more so during the pandemic.

    Fortunately, we continue to receive more donations to meet the needs of our customers.

    3) What are the benefits of providing this service?

    The greatest reward is seeing relief on our clients’ faces when we can provide a solution to their needs knowing that we have truly helped them during times of stress and uncertainty.


    Good Health Will

    Years of operation: 15.

    Number of employees / volunteers: 12 employees / around 10 volunteers (between the two stores).

    Address: 2003 W. Eighth St. in Loveland, and 2393 W. 27th St., Suite 528, in Greeley.

    Call: 970-624-6002 in Loveland and 970-515-6935 in Greeley.

    Websites: goodhealthwill.org and facebook.com/GoodHealthwill

    Good Health Will employee Joey Foncannon assembles a donated hospital bed for testing on Wednesday, December 8, 2021, outside the medical supply thrift store in Loveland. (Jenny Sparks / Loveland Reporter-Herald)
    read more
    Medical products

    FDA clears two oral drugs for COVID-19 – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

    United States: FDA clears two oral drugs for COVID-19 – Medical products supply chain review of the week

    To print this article, simply register or connect to Mondaq.com.

    Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

    • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval, the first approval from an ANDA for this product, represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
    • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives promoted by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
    • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
    • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
    • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to the ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
    • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
    • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be addressed. For devices other than in vitro diagnostics, the CDRH expects to be able to comply with the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
    • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from all causes in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
    • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

    The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

    POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

    read more
    Prescription drugs

    Florida to become the first state to import prescription drugs from Canada

    Plans to import cheaper prescription drugs from Canada have been in the works for years. In Florida, it could finally happen sooner than many realize – perhaps as early as early next year.

    Florida Health Care Administration Secretary Simone Marsiller recently told a state Senate panel, “Hopefully we can start importing in the first quarter of the new year.

    The fact that, while they differ in everything else, President Joe Biden and Governor Ron DeSantis both support her.

    “If you have drugs in Canada, the same drug costs 25 percent of what it costs here. We want Floridians to be able to share those discounts,” DeSantis said.

    A RAND study looked at drug prices in nearly 40 countries and found that the United States pays more than all prescription drugs. Average prices have risen by about 250% in the United States or, as President Biden recently noted, “about two to three times what other countries pay.”

    In the United States, insurance companies cover most of the cost of drugs for those who are insured. But those without coverage and those with insurance that doesn’t cover their particular medications burn themselves or go without.

    In Canada, prescription drugs are much cheaper because the Canadian government regulates and controls the prices. So the idea is to help Americans take advantage of Canada’s price controls.

    As you might expect, the pharmaceutical lobby opposes plans to import prescription drugs from Canada. He ran advertisements questioning the safety of using drugs imported from other countries – an advertisement even stating: “Too many have already died from counterfeit drugs; are you willing to take that risk? “

    PREVIOUS: Advertising campaign claims imported drugs are risky for Floridians

    But Governor Ron DeSantis says we can trust Canada – and Congress agrees. He passed a law allowing commercial imports of drugs from Canada in 2003. Sixteen years later, Florida was one of the first states to begin the process.

    The state has spent the past two years putting the system in place, which the governor says will keep it safe.

    “This program only applies if we show that we are providing drugs that are safe and cheaper than what we already have,” said Governor DeSantis.

    The final step is FDA clearance, and President Biden has already ordered the FDA to get to work. As soon as the FDA gives the green light, Florida plans to take action.

    PREVIOUS: Florida drug import plan moves forward

    Life Science Logistics in Lakeland is ready at this time. Its warehouses would start filling up with boxes and bottles of pills – all prescription drugs from Canada.

    “We’re ready to start importing in 90 days,” a company spokesperson told FOX 13.

    The state has not defined or announced certain details, such as which drugs will come first. State officials have suggested they could start with drugs to treat diabetes, hepatitis, COPD and / or HIV / AIDS.

    They will likely start with a small number of drugs for those with Medicaid, then for others with public insurance. Further expansion would be based on the success of the program as well as demand.

    There are some wrinkles in the plane that need to be addressed. The pharmaceutical industry is challenging it in court. And supplies can also be a problem, as Canada cannot supply its own citizens while having enough for the United States, or even all of Florida, for that matter. Shipments should be considered “surplus” or “surplus” in the Canadian market.

    But after years of planning, Florida could overcome these hurdles in 2022, triggering big changes in where we get our drugs and how much we pay for them.

    read more
    Medical supplies

    Fidelity Securities Limited donates medical supplies to police hospital

    Fidelity Securities Limited, a subsidiary of Fidelity Bank Ghana Limited, donated medical supplies to the pediatric ward of the Ghana Police Hospital in Accra.

    The supplies, including a CPAP machine, infuser, x-ray viewer, pulse oximeter, digital thermometer, pediatric ambubag, industrial nebulizer, oxygen concentrator (5L) and oxygen flow meter will help to provide health care to the children on the unit.

    Presenting the articles at Ghana Police Hospital, Edward Opare-Donkor, Board Member of Fidelity Securities Limited, said: “Fidelity Securities Limited is more than grateful for being able to fulfill its civic duty in helping to save the lives of children across the country who visit the facility. Indeed, we are committed to supporting the government in providing the best health care to the people of Ghana. “

    Mr. Opare-Donkor noted that this was only the beginning of Fidelity Securities Limited’s relationship with the Ghana Police Hospital and he encouraged the Ghana Police Hospital to continue its selfless sacrifice to the nation.

    Receiving the articles on behalf of Ghana Police Hospital, Dr Ebenezer Ewusi-Emmim, Medical Director of Ghana Police Hospital, said: “We appreciate Fidelity Securities Limited for supporting us with these valuable medical supplies at this very critical time.

    “We will use these supplies wisely while encouraging them and other commercial institutions to continue to support us in delivering first-class health services to the people of this country.”

    FSL’s support to the Ghana Police Hospital is a demonstration of its commitment to the general well-being of Ghanaians through its social impact initiatives.

    read more
    Medical supplies

    Fidelity Securities Limited donates medical supplies to Ghana Police Hospital

    Fidelity Securities Limited, a subsidiary of Fidelity Bank Ghana Limited, donated medical supplies to the pediatric ward of the Ghana Police Hospital in Accra.

    The supplies, including a CPAP machine, infuser, x-ray viewer, pulse oximeter, digital thermometer, pediatric ambubag, industrial nebulizer, oxygen concentrator (5L) and oxygen flow meter will help to provide health care to the children on the unit.

    Presenting the articles at Ghana Police Hospital, Edward Opare-Donkor, Board Member of Fidelity Securities Limited, said: “Fidelity Securities Limited is more than grateful for being able to fulfill its civic duty in helping to save the lives of children across the country who visit the facility. Indeed, we are committed to supporting the government in providing the best health care to the people of Ghana.

    Mr. Opare-Donkor noted that this was only the beginning of Fidelity Securities Limited’s relationship with the Ghana Police Hospital and he encouraged the Ghana Police Hospital to continue his selfless sacrifice to the nation.

    Receiving the articles on behalf of Ghana Police Hospital, Dr Ebenezer Ewusi-Emmim, Medical Director of Ghana Police Hospital, said: “We appreciate Fidelity Securities Limited for supporting us with these valuable medical supplies at this very critical time. We will put these supplies to good use as we encourage them and other commercial institutions to continue to support us in delivering first class health services to the people of this country. “

    FSL’s support to the Ghana Police Hospital is a demonstration of its commitment to the general well-being of Ghanaians through its social impact initiatives.

    About Fidelity Securities Limited

    Fidelity Securities Limited (FSL) is the asset management subsidiary of Fidelity Bank Ghana Limited. Licensed and regulated by the Securities and Exchange Commission of Ghana and the National Pensions Regulatory Authority, FSL is in good standing with regulators and other stakeholders.

    The main goal of FSL is to give their clients financial freedom by undertaking well documented investments on their behalf. Having operated successfully for 15+ years, FSL fully understands the Ghanaian investment landscape and has a proven track record in creating sustainable investment portfolios, which create financial stability over time. FSL manages institutional funds (pensions, provident and endowment funds among others), collective investment schemes and individual asset portfolios.

    At FSL, they are committed to demonstrating integrity, expertise and innovation to help their clients and communities grow to achieve their financial goals. This commitment is based on exceptional corporate governance standards, risk management practices, market knowledge, professionalism, proactivity and above all a customer-centric culture. Fidelity Securities was named Investment Fund Manager of the Year for the second consecutive time and Pension Fund Manager of the Year at the 2019 Ghana Accountancy and Finance Awards.

    Website: www.fidelitysecuritieslimited.com.gh

    Email: [email protected]

    LinkedIn: https://www.linkedin.com/company/fidelity-securities-limited/

    read more
    Generic drugs

    PODIUM | Bennet helps exempt generic drugs through BBB | Opinion






    Maya wheeler


    “About 18 million Americans, or 7% of American adults, say they recently couldn’t afford at least one prescription drug for their household, according to a new poll from Gallup and West Health.”

    Democrats, Republicans and Independents grapple with even insured health care costs as prescription drug prices continue to rise. No one should be forced to choose between filling their prescriptions or their rent, gas, heat or food.

    However, what is not clear is whether our elected officials choose between the people they represent and the Big Pharma lobbyists who write checks to their campaigns.

    President Biden’s Build Back Better Act includes provisions that could go a long way toward implementing these long-promised drug reform policies. The new $ 35 cap on out-of-pocket expenses for insulin for patients on commercial or health insurance plans is a big step forward for vulnerable patients.

    High drug prices disproportionately impact the sickest and poorest Americans. Nearly one in 10 Americans with three or more chronic conditions said they had to skip a drug purchase in the past three months, compared to about one in 25 people without any chronic illness, according to a Gallup poll. Skipping the purchase or rationing of drugs can be fatal. This was illustrated by NPR with the story of Nicole Smith-Holt, who lost her son three days before his next payday because he couldn’t afford to fill his insulin prescription. The price of insulin, which has no generic equivalent, has more than doubled since 2012. Those most in need of prescription drugs are also most likely to be negatively impacted by lack of access affordable drugs.

    For minority communities, access to affordable insulin is an even bigger problem. Almost one in five black adults has diabetes, a rate more than double the white patient population. The high cost of care also contributes to a higher death rate. Black Americans die twice as fast as their counterparts from diabetes.

    We have already seen the ugly health disparities in our system at the forefront of the COVID-19 pandemic, as patients of color have died at much higher rates than whites. Capping out-of-pocket spending will immediately benefit all patients, and especially those in the minority community who need help the most.

    However, the Build Back Better Act is not perfect and some provisions could actually make drugs more expensive and less accessible. The inflation price rebate penalty looks good – drug makers should not be allowed to increase their prices more than the rate of inflation. But it really only works for brand name drugs, which have a government-protected monopoly. This allows companies making the most expensive drugs to set their prices as high as they want.

    Generic drug makers, on the other hand, face much larger price fluctuations and a more competitive market, resulting in lower costs for consumers. And generic drug prices continue to decline on average year over year. The prices of brand-name drugs, meanwhile, continue to be “unsustainable, unjustifiable and unfair,” according to a recent report by Democrats in Congress. So it does not make sense to penalize a generic drug costing $ 1 for raising its price to $ 1.04, but to give a free pass to a large pharmaceutical company raising the price of its brand name drug by 10,000. $ to $ 10,299. As written, this is what the in-house version of the Build Back Better Act would do.

    Fortunately, Senator Michael Bennet and his colleagues on the Senate Finance Committee took note and exempted generic drugs from the penalty. It is the right decision, politically and, more importantly, morally.

    Generics and biosimilars account for 90% of prescriptions filled in the United States, but brand name drugs represent 80% of spending. For example, the osteoporosis drug Fosamax cost $ 2.60 per day or $ 80 per month. Now its generic version costs $ 0.28 per day, less than $ 9 per month.

    These savings and the availability of cheaper drugs could be jeopardized by these new federal government policies if they are not changed. Low-income and working-class families, as well as seniors living on fixed incomes, would be at risk.

    Senator Bennet has repeatedly shown his willingness to learn complex policies, understand its long-term impacts and make the necessary changes. The White House Biden should again heed his leadership and support the Senate version of the Build Back Better Act that makes the bill more patient-friendly.

    Elected officials have been promising drug prices to drop for a long, long time. To come so close, and then fall victim to unintended political consequences thanks to the powerful lobbying of Big Pharma, would be a grave mistake.

    Maya Wheeler is Executive Director of the African Chamber of Commerce, Colorado, and former Chair of the Colorado African American Democrats Initiative (AAICD) with the CO Democratic Party.

    read more
    Medical supplies

    HIDA: Millions of essential medical supplies delayed at congested ports

    Congestion at ports is creating a crisis for the country’s medical providers. The Health Industry Distributors Association (HIDA) told American Shipper that between 8,000 and 12,000 containers filled with millions of essential medical supplies are being delayed.

    According to HIDA, these containers are on average 37 days late.

    “COVID is always with us and it is difficult to predict the evolution of particular variants and their impact on supplies,” said HIDA President and CEO Matthew J. Rowan. “So the best strategy is for the supply chain to maintain readiness and for distributors and manufacturers to continue to get medical supplies to suppliers. “

    Federal Maritime Commissioner Carl Bentzel told American Shipper he had received letters and held follow-up meetings with representatives from HIDA, the Advanced Medical Technology Association (AdvaMed) and the International Safety Equipment Association (ISEA), all highlighting the need shipping abroad and begging for help. for port managers to identify and prioritize medical supply containers for quick pickup.

    “Although the CMF does not have the legal authority to prioritize freight, these containers contain essential products for the health, safety and well-being of our country’s frontline medical workers, as well as patients.” , said Bentzel. “President [Daniel] Maffei realizes this and we at the CMF have had several meetings on the issue and are committed to doing what we can to help healthcare providers receive these vital products.

    “The Biden administration has also helped, and we are in contact with John Porcari [port envoy to the White House Supply Chain Disruptions Task Force] on the project to ensure the delivery of essential health products to American hospitals ”

    Bentzel said he contacted Port of Los Angeles Executive Director Gene Seroka and Port of Long Beach Executive Director Mario Cordero, as well as SSA Marine, the second largest container terminal operator in the Americas, to find means of prioritizing the cargo and accelerating its movement inland.

    In March 2020, Seroka was chosen by Los Angeles Mayor Eric Garcetti to be responsible for City of Los Angeles logistics and he oversaw the Logistics Victory Los Angeles (LoVLA) response effort which assisted obtain essential personal protective equipment (PPE) and emergency services. supplies to healthcare and supply chain workers.

    “These port managers were the first to identify and move containers full of PPE and other health care and disinfection supplies at the onset of the pandemic,” Bentzel said. “Gene and Mario immediately agreed to help and set up teams at the port to move the product. They are in the process of identifying the containers. SSA is in the process of labeling the containers and using peel piles for expedited pickup.

    Seroka told American Shipper, “These supplies are more vital than ever as the omicron variant spreads across the country. HIDA has contacted us to identify the containers to be shipped. We use our digital system to identify these containers so that we can move them as quickly as possible.

    “Unfortunately, these boxes are mixed with the thousands of import containers arriving at the port. The sooner we know when these containers are arriving, the more effective we can be in fending off these valuable imports. “

    Cordero said: “Since the start of the pandemic, the Port of Long Beach, in partnership with the marine terminal operators and the stevedoring workforce, has been able to expedite shipments of PPE, supplies medical and medical equipment. Everyone has worked together to help these life-saving shipments get to hospitals and healthcare professionals as quickly as possible. This remains a priority for the entire port community.

    One of the terminals playing a key role in this supply chain mission, according to Bentzel, is SSA Marine Terminals.

    Sal Ferrigno, vice president of SSA Marine Terminals, explained that the terminals electronic platform is used to identify containers.

    “In an effort to ensure the availability of essential supplies for our country, we have prioritized medical supplies at our terminals,” Ferrigno said. “The solution is simple with the help of eModal. We are able to identify containers with medical equipment before they arrive.

    “Once unloaded from a ship, the containers are given a priority appointment where, once they leave the gate, they will be taken to their destination. The process is safe, efficient, and fast, especially when you consider the omicron virus outbreak and the need for medical supplies. “

    According to the HIDA transit analysis, congestion along the east coast is also hampering the logistical efforts of medical providers. HIDA told American Shipper that Savannah, Georgia had the most delays, followed by New York and New Jersey.

    “We spoke with Sam Ruda from the Port of New York / New Jersey and Griff Lynch from the Port of Savannah and warned them something like this was going to happen to them,” said Bentzel. “We are in the early stages of these ports. “

    Bentzel also communicated with the World Shipping Council on this logistics mission.

    “I plan to do a presentation to their members on our need for their assistance in the accelerated movement of this essential cargo,” said Bentzel. “In this insistence, we do not have adequate levels of US flag vessels under ultimate government control to assist, but I am asking for support for the delivery of this cargo.

    “The success of this initiative must involve the World Shipping Council and potentially other US coastal ports such as Savannah and New York / New Jersey. At first, they were responsive, and hopefully progress on the West Coast can lead to a heightened national effort. HIDA says hospitals urgently need these products. All facets of the maritime community should work together on this medical logistics mission. “

    read more
    Medical supplies

    HIDA: Millions of critical medical supplies delayed in congested ports

    Congestion at ports is creating a crisis for the country’s medical providers. The Health Industry Distributors Association (HIDA) told American Shipper that between 8,000 and 12,000 containers filled with millions of essential medical supplies are being delayed.

    According to HIDA, these containers are on average 37 days late.

    “COVID is always with us and it is difficult to predict the evolution of particular variants and their impact on supplies,” said HIDA President and CEO Matthew J. Rowan. “So the best strategy is for the supply chain to keep readiness and for distributors and manufacturers to keep medical supplies moving to suppliers.”

    Special FREE Masterclass! How to get started in trading in 2022 with Matt Maley! Register now!

    Federal Maritime Commissioner Carl Bentzel told American Shipper he had received letters and held follow-up meetings with representatives from HIDA, the Advanced Medical Technology Association (AdvaMed) and the International Safety Equipment Association (ISEA), all highlighting the need shipping abroad and begging for help. for port managers to identify and prioritize medical supply containers for quick pickup.

    “Although the CMF does not have the legal authority to prioritize freight, these containers contain essential products for the health, safety and well-being of our country’s frontline medical workers, as well as patients.” , said Bentzel. “President [Daniel] Maffei realizes this and we at the CMF have had several meetings on the issue and are committed to doing what we can to help healthcare providers receive these vital products.

    “The Biden administration has also helped, and we are in contact with John Porcari [port envoy to the White House Supply Chain Disruptions Task Force] on the project to ensure the delivery of essential health products to American hospitals “

    Bentzel said he contacted Port of Los Angeles Executive Director Gene Seroka and Port of Long Beach Executive Director Mario Cordero, as well as SSA Marine, the second largest container terminal operator in the Americas, to find means of prioritizing the cargo and accelerating its movement inland.

    In March 2020, Seroka was chosen by Los Angeles Mayor Eric Garcetti to be responsible for City of Los Angeles logistics and he oversaw the Logistics Victory Los Angeles (LoVLA) response effort which assisted obtain essential personal protective equipment (PPE) and emergency services. supplies to healthcare and supply chain workers.

    “These port managers were the first to identify and move containers full of PPE and other health care and disinfection supplies at the onset of the pandemic,” Bentzel said. “Gene and Mario immediately agreed to help and set up teams at the port to move the product. They are in the process of identifying the containers. SSA is in the process of labeling the containers and using peel piles for expedited pickup. “

    Seroka told American Shipper, “These supplies are more vital than ever as the omicron variant spreads across the country. HIDA has contacted us to identify the containers that need to be shipped. We use our digital system to identify these containers so that we can move them. get out as quickly as possible.

    “Unfortunately, these boxes are mixed in with the thousands of import containers arriving at the port. The sooner we know when these containers are arriving, the more effective we can be in fending off these valuable imports.”

    Cordero said: “Since the start of the pandemic, the Port of Long Beach, in partnership with the marine terminal operators and the stevedoring workforce, has been able to expedite shipments of PPE, supplies medical and medical equipment. Everyone has worked together to help these vital shipments reach the hands of hospitals and healthcare professionals as quickly as possible. This remains a priority for the entire port community.

    One of the terminals playing a key role in this supply chain mission, according to Bentzel, is SSA Marine Terminals.

    Sal Ferrigno, vice president of SSA Marine Terminals, explained that the terminals electronic platform is used to identify containers.

    “In order to ensure the availability of essential supplies for our country, we have prioritized medical supplies at our terminals,” Ferrigno said. “The solution is simple with the help of eModal. We are able to identify containers with medical equipment before they arrive.

    “Once unloaded from a ship, containers are given a priority appointment where once out of the gate they will be taken to their destination. The process is safe, efficient and fast, especially considering the omicron virus outbreak and the need for medical equipment. “

    According to the HIDA transit analysis, congestion along the east coast is also hampering the logistical efforts of medical providers. HIDA told American Shipper that Savannah, Georgia had the most delays, followed by New York and New Jersey.

    “We spoke with Sam Ruda from the Port of New York / New Jersey and Griff Lynch from the Port of Savannah and warned them something like this was going to happen to them,” Rowan said. “We are in the early stages of these ports.”

    Bentzel also communicated with the World Shipping Council on this logistics mission.

    “I plan to do a presentation to their members on our need for their assistance in the accelerated movement of this essential cargo,” said Bentzel. “In this insistence, we do not have adequate levels of US flagged ships under ultimate government control to help, but I am asking for support for the delivery of this cargo.

    “The success of this initiative must involve the World Shipping Council and potentially other US coastal ports such as Savannah and New York / New Jersey. Beforehand, they have been responsive and hopefully progress on the West Coast can lead to increased national effort HIDA says hospitals urgently need these products All facets of the maritime community should work together on this medical logistics mission.

    Image from Pixabay

    © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    read more
    Generic drugs

    Global Generic Inhalation and Nasal Spray Market Expected to Reach Over $ 10 Billion by 2026 – ResearchAndMarkets.com

    DUBLIN – (COMMERCIAL THREAD) – The report “Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative Impact of COVID -19 “has been added to ResearchAndMarkets.com offer.

    The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

    Market statistics

    The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

    Market segmentation and coverage

    This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

    • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

    • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

    • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

    • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

    • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

    • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

    Companies mentioned

    • Allergan plc

    • Altaire Pharmaceuticals inc.

    • Beximco Pharmaceuticals Ltd.

    • Catalent Pharma Solutions

    • Cipla Limited

    • Hikma Pharmaceuticals PLC

    • Mylan NV

    • Navajo Manufacturing Company Inc.

    • Pharmaceutical company Nephron

    • Perrigo Company plc

    • Preferred Pharmaceuticals Inc.

    • Sandoz International GmbH

    • Sheffield Pharmaceuticals LLC

    • Sun Pharmaceutical Industries Ltd.

    • Teva Pharmaceutical Industries Ltd.

    Cumulative impact of COVID-19

    COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insight on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

    Competitive strategic window

    The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

    FPNV positioning matrix

    The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

    Market share analysis

    The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

    Competitive scenario

    The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of the competitors, thus providing information to improve products and services.

    Main topics covered:

    1. Preface

    1.1. Objectives of the study

    1.2. Market segmentation and coverage

    1.3. Years taken into account for the study

    1.4. Currency and price

    1.5. Language

    1.6. Limits

    1.7. Hypotheses

    1.8. Stakeholders

    2. Research methodology

    3. Executive summary

    4. Market overview

    4.1. introduction

    4.2. Cumulative impact of COVID-19

    5. Market dynamics

    5.1. introduction

    5.2. Conductors

    5.2.1. Low cost associated with generic prescription drugs

    5.2.2. Increased prevalence of asthma and COPD disorders

    5.2.3. High cost of health care in developed regions

    5.3. Constraints

    5.3.1. Strict regulations for generic drugs

    5.4. Opportunities

    5.4.1. Successful drug patents expire and FDA approvals increased

    5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care

    5.5. Challenges

    5.5.1. Pressure on prices due to the presence of several players in the segment

    6. Generic Inhalation and Nasal Sprays Market, by Indication

    6.1. introduction

    6.2. Allergic rhinitis

    6.3. Asthma

    6.4. COPD

    7. Generic Inhalation Nasal Spray Drugs Market, By Age Group

    7.1. introduction

    7.2. Adults

    7.3. Children 2 to 5

    7.4. Children 6 to 12

    8. Generic Inhalation and Nasal Spray Drugs Market, By Class

    8.1. introduction

    8.2. Allergy blocker

    8.3. Anticholinergic

    8.4. Antihistamine

    8.5. decongestant

    8.6. Mast cell inhibitor

    8.7. Nasal steroid

    9. Generic inhalation and nasal sprays market, by road

    9.1. introduction

    9.2. Inhalation

    9.3. Nasal spray

    9.4. Tropical Lotion

    10. Generic inhalation and nasal sprays market, by distribution channel

    10.1. introduction

    10.2. Hospital medical store

    10.3. Online pharmacy

    10.4. Retail pharmacy

    11. America Generic Inhalation and Nasal Spray Market

    12. Asia-Pacific Generic Inhalation and Nasal Spray Market

    13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

    14. Competitive landscape

    14.1. FPNV positioning matrix

    14.1.1. Quadrants

    14.1.2. Business strategy

    14.1.3. Product satisfaction

    14.2. Market ranking analysis

    14.3. Market share analysis, by key player

    14.4. Competitive scenario

    14.4.1. Merger & Acquisition

    14.4.2. Agreement, collaboration and partnership

    14.4.3. New product launch and improvement

    14.4.4. Investment and financing

    14.4.5. Awards, recognition and expansion

    15. Company usability profiles

    For more information on this report, visit https://www.researchandmarkets.com/r/1lry5e

    read more
    Generic drugs

    Generic drugs: are they on par with more expensive brands?

    Animation: Farah Hamade

    In the United States, more than three-quarters of prescriptions are for generic drugs, non-branded drugs that can cost less than half of their branded counterparts. Generic drugs saved Americans and our health care system over $ 300 billion in 2019 alone.

    The use of generics has more than doubled over the past decade, thanks to legislation favoring the production of generic drugs and the expiration of patents on widely used drugs. Despite this enormous growth, myths about the quality of generics persist. The drug safety experts at UCSF help us understand what is the same and what is different, and whether the brand should affect your choices.


    MYTH # 1:

    Generic drugs are second-rate fakes.

    Non-branded products like spaghetti sauce or facial tissues often have a reputation for being worse – they may taste poor or be less durable than the products they imitate. Consumers sometimes associate generic drugs with second-rate fakes because of their lower prices; there is even skepticism among some suppliers.

    It is time to get rid of this lingering myth once and for all. Generic drugs are not like other non-branded products, explains Candy Tsourounis, PharmD, professor of clinical pharmacy. They are in their own highly controlled category.

    The myth of poor quality can be reinforced by the look, feel or taste of generics compared to brand name drugs that consumers are familiar with. This is because the inactive fillers, coatings, or liquids that help release the active ingredient – the drug itself – can vary.

    “A lot of people see generics as somehow inferior due to observable differences,” says Tsourounis, as generics manufacturers modify these inactive components. It also explains why brand-name over-the-counter treatments like headache or allergy medications are different from over-the-counter generics. “For example, the brand name can be a tablet with a glossy coating that tastes good and lowers easily, while the generic can be a chalky white pill with a bitter aftertaste.”

    “These differences exist, but the pharmacology – how the drug works in the body, the drug it contains and how long it takes to get to where it needs to be in the body – is the same,” explains Tsourounis, who oversees The UCSF Health Drug Formulary, the list of safe and effective drugs approved for use in the institution. “These are the most critical pieces,” she says. “The rest is just aesthetic.”


    MYTH # 2:

    Generic testing is not that rigorous.

    Generic drugs don’t go through the same testing protocols as brand-name drugs, but there’s a good reason, explains Tsourounis.

    “It’s not that the tests are less rigorous, but it’s different,” she says. It takes eight to 12 years of research and development, including clinical trials, to make sure a new drug is safe and effective. All the steps involved in bringing a drug to the market represent significant costs for the company holding the patent.

    However, generics are not new drugs. When the patent becomes available on an existing approved drug, a generic manufacturer simply purchases or produces the already developed, tested and approved active component and formulates it into a tablet, capsule or other delivery vehicle. “This timeline is month, not years, ”says Tsourounis, so it costs a lot less to bring a generic drug to the market. When multiple manufacturers produce the same generic drug, competition drives prices down further.

    The FDA requires that generics contain the same active ingredient as the branded version, have the same strength and format (such as a tablet or capsule), and use the same route of administration (such as by mouth or injection. ). To prove that their formulations work like the original drug, generic manufacturers must meet strict bioequivalence requirements, which means that the drug must be absorbed by the body and measurable in the blood at comparable levels, in a strict range, to those of the brand. drug name.

    Tsourounis also points out that FDA regulations govern every detail of pharmaceutical manufacturing, from laboratory facilities to the training required for people who handle and package drugs.

    Shalini Lynch, PharmD ’92, associate professor of clinical pharmacy, co-authored a study that found that generic drug skepticism is higher among auxiliary providers like nurses and medical assistants, who receive limited training in pharmacology, than among doctors. “Additional training on specific concepts such as bioequivalence,” explains Lynch, “could… promote a better understanding of the generic approval process.”


    MYTH # 3:

    Generics just don’t work as well as brand name drugs.

    Especially when people switch from a brand name drug to a generic drug, they can experience modest changes. Tsourouni says to avoid jumping to the conclusion that the credits don’t measure up.

    “There is a lot to assess before concluding that the generic drug does not work as well as the brand,” she says. Are there interactions with food or other drugs that affect the way the drug is absorbed? Does the person take the medicine at the same time each day? When she hears complaints that a drug didn’t work as quickly or caused a side effect, “there is usually no pharmacological reason for these effects, so I turn to other causes or maybe. even be a placebo effect based on these myths that generics aren’t as good, ”she said.

    Pharmacies stock both generics classified as AB – drugs with the highest bioequivalence ratings – and drugs classified as B, which still meet strict FDA requirements but have slightly lower bioequivalence. Generics classified as B may be better suited for the initial use of a drug rather than replacing a branded version. While Lynch warns that additional monitoring may be needed for patients with conditions where small changes in blood levels could pose “immediate and serious risks,” she says the warning is about the situations and risks individual, not drug classes. Lynch and Tsourounis say that it is beneficial for all patients to discuss generic drug options with their doctor.

    “The bottom line is that generic drugs provide the same active ingredient as the brand at a lower cost, and they should be used whenever appropriate,” Tsourounis explains. “These are good drugs. “

    read more
    Medical supplies

    Henry Schein’s new contract (HSIC) expands medical supplies arm

    Henry Schein, Inc. HSIC recently entered into a cooperation contract with OMNIA Partners to expand into the field of point-of-care testing, personal protective equipment (PPE) and essential medical supplies. OMNIA Partners is considered the country’s largest purchasing organization for public and private markets.

    The partnership is expected to expand Henry Schein’s access to the aforementioned fields in academia and public health. However, the financial terms of the deal were not disclosed.

    Details of the agreement

    Henry Schein has indicated that the product and supplies from this partnership will be available through Henry Schein Medical University Health. The company has entered into a master distribution agreement with the University of California. This framework agreement covers the distribution of medical supplies to the University of California and all eligible public organizations registered with OMNIA partners.

    According to Henry Schein, this framework agreement will help increase savings and support, and provide easy access to COVID-19 testing and services. This will therefore help the company to better serve its “medical” customers involved in university health, K-12 education, local and national government health care, and first aid services. In addition, this master agreement will also offer supplies of medical products, laboratory, treatment room and equipment, pharmaceuticals, vaccines, influenza, education, training and simulation to help meet the challenges. needs of student health centers, physiotherapy, occupational therapy, sports clients in medicine, sports training, laboratory and pharmacy.

    Strategic importance

    According to Henry Schein, this cooperation contract with OMNIA Partners will help streamline the procurement process for the company’s clients within its medical wing. This collaboration aims to help HSIC customers gain comprehensive options for purchasing the medical products and supplies they need to maintain the health and well-being of the public, as well as students and staff.

    Image source: Zacks Investment Research

    Additional benefits of this contract include support from sales and service specialists, and expanded access to Henry Schein Medical’s product portfolio.

    Recent notable developments

    In December 2021, Henry Schein’s orthodontic company, Henry Schein Orthodontics, released Studio Pro 4.0, an online treatment planning software for Reveal Clear Aligners. Reveal is the clear solution that helps clinicians meet their patients’ requests for transparent aligners. It features direct integrations with many leading intraoral scanners as well as direct connections with practice management software. Henry Schein Orthodontics supplies a variety of orthodontic products to dental markets around the world.

    In June 2021, Henry Schein entered into a $ 53.4 million nationwide storage contract with the US Department of Health and Human Services (HHS). The terms of the contract require the company to provide storage and innovative logistical support for 80,000 pallets of personal protective equipment (PPE) and COVID-related products to healthcare professionals.

    In May 2021, the company acquired a 70% stake in eAssist Dental Solutions (eAssist). This acquisition will help the company fulfill its mission of providing cutting-edge solutions that help dental practices operate more efficiently and cost effectively, allowing them to focus more on patient care.

    Share price return

    The stock has underperformed its industry over the past year. It increased by 9% compared to the industry growth of 13.5%

    Rank of Zacks and choice of keys

    Henry Schein currently wears a Zacks Rank # 3 (Hold).

    Some better classified actions of the wider medical space are Chemed Company CHE, Corporation of America Holdings Laboratory, Where LabCorp LH and Medpace Holdings, Inc. MEDP.

    Chemed has a long-term profit growth rate of 7.7%. The company has beaten earnings estimates in three of the past four quarters and missed one, delivering a surprise of 5.6% on average. He currently wears a Zacks Rank # 2 (Buy).

    Chemed has outperformed its industry over the past year. CHE gained 3.7% against a drop of 35.6% for the industry.

    LabCorp announced third quarter 2021 adjusted EPS of $ 6.82, beating Zacks’ consensus estimate by 42.9%. Revenue of $ 4.06 billion was 13.4% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 2. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.

    LabCorp has an estimated long-term growth rate of 10.6%. LH has beaten estimates over the past four quarters with an average surprise of 25.7%.

    Medpace announced third quarter 2021 adjusted EPS of $ 1.29, beating Zacks’ consensus estimate by 20.6%. Revenue of $ 295.57 million was 1.2% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 1.

    Medpace has an estimated long-term growth rate of 16.4%. The MEDP has beaten estimates over the past four quarters, with an average surprise of 11.9%.

    Boom in infrastructure stocks will sweep America

    A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.

    The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “

    Zacks published a special report to help you do just that, and today it’s free. Discover 5 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as transporting goods and transforming energy on an almost unimaginable scale.

    Download FREE: How to Profit from Billions of Dollars in Infrastructure Spending >>

    Click to get this free report

    Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

    Henry Schein, Inc. (HSIC): Free Stock Analysis Report

    Chemed Corporation (CHE): free share analysis report

    Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report

    To read this article on Zacks.com, click here.

    Zacks investment research

    The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

    read more
    Medical supplies

    Henry Schein’s New Deal (HSIC) Expands Medical Supplies Arm – December 14, 2021

    Henry Schein, Inc. (HSIC Free Report) recently entered into a cooperation contract with OMNIA Partners to expand into the field of point-of-care testing, personal protective equipment (PPE) and essential medical supplies. OMNIA Partners is considered the country’s largest purchasing organization for public and private markets.

    The partnership is expected to expand Henry Schein’s access to the aforementioned fields in academia and public health. However, the financial terms of the deal were not disclosed.

    Details of the agreement

    Henry Schein has indicated that the product and supplies from this partnership will be available through Henry Schein Medical University Health. The company has entered into a master distribution agreement with the University of California. This framework agreement covers the distribution of medical supplies to the University of California and all eligible public organizations registered with OMNIA partners.

    According to Henry Schein, this framework agreement will help increase savings and support, and provide easy access to COVID-19 testing and services. This will therefore help the company to better serve its “medical” customers involved in university health, K-12 education, local and national government health care, and first aid services. In addition, this master agreement will also offer supplies of medical products, laboratory, treatment room and equipment, pharmaceuticals, vaccines, influenza, education, training and simulation to help meet the challenges. needs of student health centers, physiotherapy, occupational therapy, sports clients in medicine, sports training, laboratory and pharmacy.

    Strategic importance

    According to Henry Schein, this cooperation contract with OMNIA Partners will help streamline the procurement process for the company’s clients within its medical wing. This collaboration aims to help HSIC customers gain comprehensive options for purchasing the medical products and supplies they need to maintain the health and well-being of the public, as well as students and staff.

    Image source: Zacks Investment Research

    Additional benefits of this contract include support from sales and service specialists, and expanded access to Henry Schein Medical’s product portfolio.

    Recent notable developments

    In December 2021, Henry Schein’s orthodontic company, Henry Schein Orthodontics, released Studio Pro 4.0, an online treatment planning software for Reveal Clear Aligners. Reveal is the clear solution that helps clinicians meet their patients’ requests for transparent aligners. It features direct integrations with many leading intraoral scanners as well as direct connections with practice management software. Henry Schein Orthodontics supplies a variety of orthodontic products to dental markets around the world.

    In June 2021, Henry Schein entered into a $ 53.4 million nationwide storage contract with the US Department of Health and Human Services (HHS). The terms of the contract require the company to provide storage and innovative logistical support for 80,000 pallets of personal protective equipment (PPE) and COVID-related products to healthcare professionals.

    In May 2021, the company acquired a 70% stake in eAssist Dental Solutions (eAssist). This acquisition will help the company fulfill its mission of providing cutting-edge solutions that help dental practices operate more efficiently and cost effectively, allowing them to focus more on patient care.

    Share price return

    The stock has underperformed its industry over the past year. It increased by 9% compared to the industry growth of 13.5%

    Rank of Zacks and choice of keys

    Henry Schein currently wears a Zacks Rank # 3 (Hold).

    Some better classified actions of the wider medical space are Chemed Company (CHE Free report), Corporation of America Holdings Laboratory, Where LabCorp (LH Free report) and Medpace Holdings, Inc. (MEDP Free report).

    Chemed has a long-term profit growth rate of 7.7%. The company has beaten earnings estimates in three of the past four quarters and missed one, delivering a surprise of 5.6% on average. He currently wears a Zacks Rank # 2 (Buy).

    Chemed has outperformed its industry over the past year. CHE gained 3.7% against a drop of 35.6% for the industry.

    LabCorp announced third quarter 2021 adjusted EPS of $ 6.82, beating Zacks’ consensus estimate by 42.9%. Revenue of $ 4.06 billion was 13.4% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 2. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.

    LabCorp has an estimated long-term growth rate of 10.6%. LH has beaten estimates over the past four quarters with an average surprise of 25.7%.

    Medpace announced third quarter 2021 adjusted EPS of $ 1.29, beating Zacks’ consensus estimate by 20.6%. Revenue of $ 295.57 million was 1.2% higher than Zacks’ consensus estimate. He currently wears a Zacks Rank # 1.

    Medpace has an estimated long-term growth rate of 16.4%. The MEDP has beaten estimates over the past four quarters, with an average surprise of 11.9%.

    read more
    Generic drugs

    Generics and biosimilars get last-minute stay of rebates with Senate adjustments for Build Back Better Act – Endpoints News

    The Senate Finance Committee on Saturday released the latest text of President Joe Biden’s $ 2 trillion spending plan, paid at least in part with new bargaining power for Medicare and inflation discounts that manufacturers of drugs will have to pay if their drug prices rise too quickly each year.

    But now generic drugs threatened with shortages and biosimilars have been excluded from discounts, as demanded by their industry lobby groups. They said the inclusion of such discounts and negotiations could increase the likelihood of drug shortages and create barriers to competition.

    According to the latest version of the text of the bill, generic Part D drugs that are in short supply may be exempted, as well as biosimilars, and the secretary of the HHS may make certain decisions that a drug may be eligible for a reduction. or a waiver, if access to the drug would be severely reduced.

    Unlike Medicaid, under current law Medicare does not have the power to limit annual price increases for drugs covered by Part B or D. Rebuild Better Act would require drugmakers, starting in 2023, to remit the federal government if their prices for single-source drugs and biologics rise faster than the rate of inflation, according to KFF.

    Manufacturers who do not pay this discount would be penalized and forced to pay at least 125% of the original discount.

    The Congressional Budget Office (before the exclusion of generics and biosimilars) estimated that the net reduction in the federal deficit through rebates would be around $ 84 billion over 10 years (through 2031). The CBO also estimated that about 10 fewer drugs (out of a calculated total of 1,300 drug approvals) over 30 years would not be developed because of the lost money.

    Finance Chairman Ron Wyden (D-OR) said in a statement: “Our package is historic. It would create well-paying jobs, lower the cost of raising a family, tackle the climate crisis and lower energy bills, build more affordable housing, and lower health care costs for families and the elderly.

    read more
    Prescription drugs

    The Incredibly High Price of Prescription Drugs national news


    Insulin is a medical wonder, saving the lives of millions of people who would otherwise die of diabetes. It can also be prohibitively expensive, going up to $ 300 a vial for newer versions of the treatment, which patients with diabetes need two to three times per month.

    For patients with less common ailments, the sticker shock can be much worse. Do you have a small child with spinal muscular atrophy, a rare genetic condition that weakens muscles, causes movement problems over time and can be fatal? The good news is that the Food and Drug Administration in 2019 approved a drug, Zolgensma, a one-off curative therapy. The bad news is that it costs over $ 2.1 million – and may not be covered by insurance – making it the most expensive drug in the world.

    The prices of prescription drugs in America are a constant source of frustration, anger and bewilderment among patient-consumers. Why are some drugs so expensive – and why are some pills significantly more expensive than the same drug sold overseas? Who decides the price of prescription drugs – and how do you make them affordable without stifling the innovation and research that has produced the miracle cures patients enjoy today?

    Political cartoons about Congress

    Congress is grappling with this problem now, examining provisions of the “Build Better” bill that seek to reduce the burden on consumers by capping the co-payments patients are supposed to cover and annual out-of-pocket expenses in some cases. circumstances. As is is currently written, the measure would allow Medicare to negotiate drug prices – something the government was specifically prohibited from doing when Medicare Part D, the prescription drug benefit for the elderly, was created in 2003.

    The new measure would also impose a tax penalty if drug companies raised prices more than inflation, capped insulin co-payments to $ 35 per month, and capped out-of-pocket expenses for the elderly at $ 2,000 for the elderly. drugs covered by Medicare.

    Many Democrats have portrayed the battle as a battle between helpless patients and drugmakers chasing dollars. Republicans say efforts to set prices, even in a roundabout way, will discourage the development of the very treatments that save lives.

    “The public truly have a love-hate relationship with the pharmaceutical industry. They appreciate and appreciate the role of the pharmaceutical industry” in developing treatments that change and save lives, Mollyann Brodie, Executive Vice President of health research group Kaiser Family Foundation said in a webinar this week. “On the other hand, they also think the industry is too profit-oriented and the profits are too high.”

    The industry, represented by the powerful Pharmaceutical Research and Manufacturers of America (PhRMA), certainly has its bogeymen. Chief among them is Martin Shkreli, the so-called “pharmaceutical brother” who sparked anger in 2015 when his company, Turing Pharmaceuticals, increased the price of a life-saving drug, Daraprim, from $ 13.50 to $ 750 per tablet. (Shkreli is in prison for security fraud. Turing and his parent company agreed wednesday to pay $ 40 million to settle a case alleging stealing from patients).

    But pharmaceutical companies have also developed critical therapies and groundbreaking research in diseases ranging from cancer to Alzheimer’s disease. They may have saved humanity through the rapid development of vaccines (and a possible new treatment) against the COVID-19 virus.

    But why are some drugs so expensive? And what can be done to make therapy more affordable?

    The answer is much more complicated than it looks, experts say. And the solutions aren’t as straightforward as viewing the manufacturers as the sole source of the problem.

    “Everyone likes to find the bad guys,” says Wayne Winegarden, director of the Center for Medical Economics and Innovation at the Pacific Research Institute. Aside from some known bad actors (like Shkreli), “there is no bad guy here. We have a really bad health care system that incites all kinds of crazy behavior,” Winegarden says.

    Drug prices, experts explain, are determined by various players. A manufacturer sets an “introductory price” – which will usually be higher if it is a new treatment or a breakthrough treatment. An intermediary, called the Pharmacy Benefit Manager, then negotiates discounts and rebates with manufacturers for the drug, which they then provide to pharmacies, doctors and hospitals.

    But Pharmacy Benefit Managers don’t necessarily pass the discount on to patients, says Leslie Dach, president of the healthcare reform group Protect Our Care. They also don’t reveal how much of the rebate they got, so patients don’t know what the true cost is.

    Insurance may very well cover a particular drug, explains Dach. But since the co-payment is based on the original manufacturer’s price – not the lower negotiated cost paid by the Pharmacy Benefit Manager – the patient ends up paying more.

    “Everything here is a black box,” he says.

    Pharmacies are also at an impasse, says Douglas Hoey, CEO of the National Community Pharmacists Association. Pharmacy Benefit Managers – three of whom, he says, control 80% of the market – are “incredibly powerful with health care providers.” Intermediary companies can, for example, refer patients to pharmacies in the network and say to pharmacies: “If you do not take our prices, we will refer this patient elsewhere”.

    This means that even when the initial cost of a drug goes down, a patient may not see the benefit. A report by Milliman, commissioned and released this week by PhRMA, found that the net price of insulin in 2021 was, on average, 84% lower than the list price due to discounts, rebates and other payments. But experts note that a decrease in the net and reduced price does not necessarily mean that the patient’s co-payment will be lower. The study singled out Pharmacy Benefit Managers, saying that companies “have been found to favor products with high list prices and large discounts over lower list price equivalents,” with “unintended consequences” for them. patients whose co-payment is based on the original list prices.

    The Pharmaceutical Care Management Association, which represents Pharmacy Benefit Managers, blamed the manufacturers, noting that the high prices start there.

    “Ironically, the industry that controls the list price of prescription drugs has tried to point the finger at those who focus on reducing the cost of prescription drugs to patients and payers,” the group said in a statement.

    It’s true that manufacturers set original prices, says Rena Conti, professor at Boston University, associate research director of biopharmacy and public policy at the university’s Institute for Health System Innovation and Policy. . But she says the answer isn’t simply to penalize the profitable industry.

    “There are a lot of very misaligned incentives that create a lot of headaches for real people at the pharmacy counter,” said Conti, who is due to testify on the matter before a House committee on Friday. “We are also the beneficiaries of a very robust pharmaceutical industry that is actually bringing new products to market, some of which are really transforming our lives. “

    “The point here is not to punish but rather to really think about how we might have the opportunity to realign the incentives,” she adds. For patients paying thousands of dollars or more for essential medicines, this change cannot come soon enough.

    read more
    Generic drugs

    Corporate Rx for Distressed Healthcare System: Affordable Generics Made in USA

    Nexus Pharmaceuticals founder Mariam Darsot believes in altruistic acts like funding a labor and delivery ward in Sierra Leone, the country with the highest maternal mortality rate in the world. Photograph of Evan Jenkins

    Nexus Pharmaceuticals is a 2021 Inc. Best in Business winner. With the second annual Best in Business, Inc. award recognizes companies that have made an exceptional impact on their industries, communities, the environment and society as a whole.

    Meet the Illinois-based family-owned pharmaceutical company investing in nationwide manufacturing of drugs as treatment for the struggling healthcare industry.

    Nexus Pharmaceuticals unveiled a state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin in June, doubling down on its mission to make high-quality generic drugs more affordable and accessible to patients in the U.S. The company’s three-story building, an investment of $ 250 million that will eventually employ more than 400, is the first national project of its kind in three decades. Meanwhile, production of US pharmaceuticals has largely shifted overseas so companies can take advantage of reduced environmental regulations and a lower-cost workforce. Today, only 28 percent of the active pharmaceutical ingredients supplied to the United States are produced here.

    This over-reliance on foreign manufacturers has resulted in supply chain issues, quality-related recalls, and reduced export availability. All of this has contributed to rising pharmaceutical prices and national shortages, according to Mariam Darsot, CEO and founder of Nexus. And that, she says, prevents people from getting the timely treatment they might need. Also at the start of the pandemic, Indian manufacturers reduced exports of more than 20 essential pharmaceuticals and active ingredients to meet patient demand in their own country, which only added to the already heavy burden. of American health. the care industry, explains Darsot.

    “I think it’s fair to say that the pharmaceutical industry has damaged its reputation a lot through price fixing allegations, substandard products from overseas or price increases. essential drugs, ”Darsot said. And she is committed to changing the industry, from the inside out. Since its inception in 2003, Nexus has prioritized the production of injectable drugs with historically rare critical needs. It has a long history of working with contract manufacturers to produce its FDA-approved generic pharmaceuticals, and now, with its own manufacturing facility, it can scale up its production even further to have a serious impact on the overall drug supply of consumers. United States. (Especially considering the fact that most of the drug shortages in the country are in generic drugs, Nexus’ specialty, the promise is clear.)

    Over the past year, the company has already increased the US supply of two rare and life-saving pharmaceuticals: an injection of succinylcholine chloride, a drug in high demand to treat Covid patients, and an injection of potassium chloride, an IV solution with historically few manufacturers (including the one damaged in Hurricane Maria, resulting in a lasting shortage).

    Darsot says she’s not interested in profit for profit – the company explicitly produces drugs that are needed in an attempt to lower healthcare costs for consumers. Nexus avoids private equity so as not to be influenced by shareholders. His altruism also extends beyond his core business. In 2020, for example, Nexus funded a labor and delivery unit at the Tanihanun health center in Sierra Leone, the country with the highest maternal mortality rate in the world. In 2021, the company also donated $ 176,000 to charitable organizations through employee matchmaking and community partnerships.

    “Being a family business allows us to give back to a community that has given so much to our business and our family,” said Darsot. “This brings us back to our core mission of helping deliver affordable medicines to those who need them most.”

    EXPLORE MORE Best in business COMPANIESRectangle

    Extract from the Winter 2021/2022 issue of Inc. Magazine

    read more
    Medical supplies

    Over $ 1 million in medical supplies to be delivered to rural African villages by Denver organizations

    COVID has only made the problem worse and made it more difficult for rural areas to obtain medical supplies. From personal protective devices (PPE) to life-saving supplies to basic durable health goods, global demand has caused serious supply chain problems and rising prices. For rural and poor communities that already suffer from a lack of resources, this often means going without significant medical care and supplies.

    “Our medical staff is at the service of patients in Denver every day “, said Shay kerman, COO of Emergency Care Solutions at Denver. “It’s easy to take for granted access to high-quality medical care like we have here, while other places suffer from lack of access to basic medical supplies and life-saving equipment. “

    To help meet this need, Urgent Care Solutions and Project CURE have teamed up to send two containers of durable medical goods to Ghana and Senegal. Urgent Care Solutions pays the cost and their team members help collect the supplies and ship them to Africa.

    “I saw the need firsthand,” Kerman said. “During my work in Ghana with groups of volunteers providing medical assistance, I saw tiny villages that had limited access to water, let alone medical supplies. “

    At November 10e, Dairus and Shay Kerman, along with staff from AFC Urgent Care Denver, helped sort, assemble, pack and ship medical supplies to Project CURE’s nonprofit headquarters in Centenary, CO.

    Medical supplies worth millions will be distributed by local health care providers.

    “I am very excited about this partnership. Our head office is here in Denver and donations from a local organization like Urgent Care Solutions help us fulfill our mission, ”said Dr. Douglas jackson, President and CEO of Project CURE “Due to COVID, there is an even greater need for medical services and supplies in underserved countries. “

    The CURE project provided more than $ 48 million in medical supplies donated in the United States and abroad. Donated medical supplies and equipment are provided free of charge to local health care providers serving remote areas.

    About emergency care solutions

    Urgent Care Solutions dba AFC Urgent Care has 9 sites serving more than 150,000 patients each year in Denver and Aurore, Colorado. AFC Urgent Care provides prompt and comprehensive medical care with short wait times and reasonable rates.

    About the CURE project

    Project CURE is the world’s largest distributor of donated medical equipment and supplies. They deliver these supplies to resource-limited communities around the world in more than 135 countries. Project CURE accepts donations from medical supply companies, hospitals, healthcare providers, and consumers.

    Linked in the publication

    Emergency care solutions in Denver is partnering with Project CURE to send millions of dollars in medical supplies to rural African villages in desperate need. Yesterday, the medical staff and management of Urgent Care sorted, assembled, packed and shipped much-needed medical supplies.

    SOURCE Emergency Care Solutions

    read more
    Medical products

    Medical Products Supply Chain Week Review – October 28, 2021 – Food, Medicines, Healthcare, Life Sciences

    United States: Medical Products Supply Chain Weekly Review – October 28, 2021

    To print this article, simply register or connect to Mondaq.com.

    Over the past week, the FDA’s Vaccines and Related Biologics Advisory Committee recommended authorization of the Pfizer-BioNTech vaccine for use in children 5 to 11 years of age. The CDC has officially approved the booster dose for Moderna and J&J vaccines. President Biden met with Dr. Robert Califf for the top FDA post. Please see details of these and other supply chain developments below:

    • On October 21, the CDC director approved the Advisory Committee on Immunization Practices (ACIP) recommendations for Moderna and J&J booster doses. The move comes after both vaccines received Emergency Use Clearance (EUA) from the FDA. The indication for the Moderna booster is administration six months after the end of the initial vaccination schedule at two doses for people aged 65 years and over, people aged 18 to 64 years with risk factors for serious disease and those whose profession puts them at risk. risk of exposure. For the J&J booster, the indication is administration two months after a first vaccination for all individuals aged 18 and over. The CDC has also approved FDA clearance to mix and match dosing from different manufacturers.
    • On October 22, President Biden met with Dr. Robert Califf to discuss the possibility of leading the FDA. Califf previously served as FDA Commissioner from February 2016 to January 2017. Califf is the Donald F. Fortin MD Distinguished Professor of Cardiology at Duke University School of Medicine. He is also the founding director of the Duke Clinical Research Institute and a member of the National Academy of Medicine. No official announcement was made.
    • On October 22, the administration announced that investments had been made in the manufacturing supply chain to expand the availability and use of home COVID-19 tests, including rapid tests. More recently, the FDA cleared the Celltrion DiaTrust COVID-19 Ag Home test, which is intended for use as a home test that can be used without a prescription. The FDA has also reissued the EUA for the Quidel QuickVue At-Home OTC COVID-19 test to include home use without a prescription. The Department of Health and Social Services and the Department of Defense have awarded more than $ 500 million in contracts to companies dedicated to this effort. The Authority has pledged to invest $ 3 billion by the end of the year. To date, 419 tests and specimen collection devices have received an EUA; however, only 15 home tests were authorized.
    • On October 26, the FDA’s Vaccines and Related Biologics Advisory Committee recommended granting an EUA for Pfizer-BioNTech’s COVID-19 vaccine for children ages 5 to 11. The two-dose regimen would be a lower dose (10 micrograms per vaccine) than vaccines used in people 12 years of age and older. If the FDA changes the EUA for the vaccine, ACIP will vote on the recommendations at its meeting on November 2-3, 2021.
    • On October 27, the FDA, Health Canada and the UK Medicines and Health Products Regulatory Agency jointly published 10 Guiding Principles for the Development of Good Machine Learning Practices (GMLP). The principles are intended to lay the foundation for international collaborative organizations (such as the International Forum of Medical Device Regulators) to advance the maturation of GMLPs.

    The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

    POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

    read more
    Medical products

    Results of medical products actions on November 2: IDXX, STE and more

    The latest earnings forecast reflects a stable quarterly performance for the medical industry so far this reporting cycle. According to the industry scorecard, 25.5% of companies in the medical sector, constituting nearly 47.6% of the industry’s market capitalization, reported profits until October 27. Of these, 78.6% exceeded profit estimates and 85.7% exceeded the same for income. Profits increased 19.6% year-on-year to revenues up 12.1%.

    This scoreboard reflects the stability in the United States over the gradual reopening of the economy even amid the rise of the Delta variant. However, supply chain disruptions are still significant due to international restrictions in many geographies. In addition, many parts of the international market affected by COVID are still suffering due to declining cash flow and difficult economic conditions.

    Overall, the medical sector’s third-quarter profits are expected to rise 19.5% on a sales increase of 12.6%. This compares to second quarter reported profit growth of 32.1% and revenue growth of 21.3%.

    Quarterly synopsis of medical products

    The dynamic nature of the COVID-19 crisis is rapidly transforming the landscape of the medical products industry. Growth in the collective operations of medical product companies (within the broader medical sector) improved significantly in the second quarter, with the phasing out of restrictions. But the third quarter reporting cycle has so far shown a steep sequential decline in the core business inherited from the companies.

    However, thanks to fiscal and monetary stimulus measures and the mass vaccination campaign inside and outside the country, the process of reopening the economy has never stopped. The current reporting cycle shows that hospital visits and core hospital activities slowed temporarily in July and August, but picked up sharply in September.

    On the other hand, with the increase in the number of cases, manufacturers of tests, vaccines and therapeutics have seen massive market adoption of their COVID-related health care support products and services in the third quarter. trimester.

    Specifically, the third quarter results for medical product inventories so far have shown a temporary decline in baseline activity compared to the second quarter. At the same time, inventories of diagnostic tests, which had seen a slowdown in demand for COVID-19 tests in the second quarter, picked up momentum in the third quarter, in line with industry trends.

    Zacks’ medical products business is currently ranked in the bottom 38% (156 out of 254 industries).

    Let’s take a look at four medics players who are expected to report their results on November 2.

    IDEXX Laboratories, Inc. IDXX: In the third quarter, IDEXX’s Companion Animal Group (CAG) business is expected to have benefited from consistent and healthy organic revenue growth, supported by strong organic growth in recurring CAG diagnostics revenue in the United States. United and internationally. Robust growth in clinical activities in the United States is likely to have contributed to CAG Diagnostic’s recurring revenue gains in the United States. When releasing its second quarter results, the company noted 13% growth in clinical visits to the United States, with strength in the “non-wellness” and “wellness” visit categories. The CAG branch likely benefited from organic growth in revenues from CAG diagnostic instruments, as it did in the previous quarter. (Learn more: IDEXX to Report Third Quarter Revenue: What’s in the Cards?)

    Zacks’ consensus estimate for third quarter earnings per share is set at $ 1.88. Revenue is expected to be $ 793.3 million.

    IDEXX has the right combination of two key ingredients – a positive winning ESP and a Zacks # 3 (Hold) or better ranking – which increases the odds of a winning winning streak.

    The company has + 2.77% ESP revenue and Zacks # 3 rank.

    You can discover the best stocks to buy or sell before they are flagged with our ESP Earnings Filter.

    You can see The full list of Zacks # 1 Rank (Strong Buy) stocks today here.

    IDEXX Laboratories, Inc. Price and EPS Surprise

    IDEXX Laboratories, Inc. price-eps-surprise | Quote IDEXX Laboratories, Inc.

    STERIS plc STE: The Applied Sterilization Technologies (AST) arm of the company likely benefited from increased customer demand for medical devices in the second quarter of fiscal 2022, as it did in the previous quarter. The company expects this branch to remain strong as its major medical device customers continue to benefit from the rebound in procedures and some inventory replenishment. Additionally, demand for COVID-related products and vaccines as well as disposables for bioprocess manufacturing is expected to remain strong, which will benefit the AST arm. (Read More: STERIS to Announce Q2 Revenue: What’s in the Cards?)

    Zacks’ consensus estimate for the second quarter of fiscal 2022 is set at earnings per share of $ 1.83. Revenue is expected to reach $ 1.16 billion.

    The company has ESP income of 0.00% and Zacks Rank 2 (buy).

    STERIS plc Price and EPS Surprise

    STERIS plc Price and EPS Surprise

    STERIS plc price-eps-surprise | STERIS plc quote

    Henry Schein, Inc. HSIC: According to Henry Schein’s August 2021 update, the company has seen increased demand in the global dental and medical markets for the gradual reopening of practices and stable patient traffic around the world over the course of recent months, even in countries with stricter foreclosure rules. This recovery trend is expected to continue throughout the third quarter of 2021, thus increasing the company’s turnover. (Read more: What’s next for Henry Schein in third quarter results?)

    Zacks’ consensus estimate for the third quarter is set at 94 cents per share. Revenue is expected to reach $ 2.94 billion.

    The company has an ESP on earnings of +1.06% and a Zacks # 2 rank.

    Henry Schein, Inc. Awards and EPS Surprise

    Henry Schein, Inc. Awards and EPS Surprise

    Henry Schein, Inc. price-eps-surprise | Quote from Henry Schein, Inc.

    Omnicell OMCL: In recent months, Omnicell has benefited from the strength of its business model and its strategic positioning in the market. In the midst of the pandemic, the corporate healthcare system and retail pharmacy customers have shown greater acceptance of the fully self-contained pharmacy. As a result, demand for Omnicell’s end-to-end automation solutions has grown. The company, in August, said it was on track to meet its five-year target company goal initiated earlier this year. All of these developments are expected to have contributed significantly to the company’s revenue in the third quarter of 2021.

    Zacks’ consensus estimate for third quarter earnings per share is set at 91 cents. Revenue is expected to be $ 283.8 million.

    The company has an ESP on earnings of 0.00% and a Zacks # 2 rank.

    Omnicell, Inc. Awards and EPS Surprise

    Omnicell, Inc. Awards and EPS Surprise

    Omnicell, Inc. price-eps-surprise | Omnicell Quote, Inc.

    Boom in infrastructure stocks will sweep America

    A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.

    The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “

    Zacks published a special report to help you do just that, and today it’s free. Discover 7 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as transporting goods and transforming energy on an almost unimaginable scale.

    Download FREE: How to Profit from Billions of Dollars in Infrastructure Spending >>

    Click to get this free report

    Omnicell, Inc. (OMCL): Free Stock Analysis Report

    Henry Schein, Inc. (HSIC): Free Stock Analysis Report

    IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

    STERIS plc (STE): Free Stock Analysis Report

    To read this article on Zacks.com, click here.

    Zacks investment research

    The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

    read more
    Generic drugs

    Increasing the use of generic drugs is an anti-inflationary tactic

    We hear these days of alarming growth in inflation, especially in housing and gasoline. That dreaded “I” word permeates discussions as affordability becomes a dominant issue.

    One area that could actually see prices drop, however, is our prescription drug coverage.

    We are used to assuming that our health care system is better than that of our southern friends, but in reality Americans have over 90% of their prescription drugs filled with generics, whereas in Canada we we only have about 73%.

    Generic drugs have the same ingredients, undergo the same rigorous testing and are just as safe and effective, the only difference is that they are more affordable than branded options. For example, if we increased our prescription drug coverage through generic drugs by just 1%, we could save more than $703 million.

    This is a critical public policy area where governments could realize significant savings.

    But it is also an area where consumers themselves, and employers, can make significant savings in this time of rising prices. Indeed, this is an area where HR personnel and others making decisions about employee drug plans have the opportunity to save money for everyone involved.

    As one insurance broker recently noted, “I’ve never been able to convince a client to include the mandatory generic clause. Given the right information, my clients take this for granted. It is simply a question of education.

    We need to make this “evidence” a reality by ensuring that all employers have generic drug substitution policies to encourage patients and prescribers to choose the most cost-effective drugs. This means that the drug plan would reimburse at cost a generic drug rather than a more expensive brand name option, which would result in savings for the employer and for the employee, who would obtain the same medical ingredients at a lower price. cost.

    This change means that insurance coverage is further extended to reduce the employee’s out-of-pocket expenses. Such a change would maximize their shared dollars so everyone involved would have more money to redirect to other priorities.

    Provinces in Canada deal with designating generic drugs as “interchangeable” with branded versions, and many insurers rely on public formulary listings for mandatory generic substitution policies. Provinces should do a better job of making generic substitution more readily available so that patients and employers can realize this savings potential.

    Specifically, in Saskatchewan and Manitoba, interchangeability is limited to publicly funded drugs, which limits access to low-cost generic versions of prescription drugs not covered by government drug plans. Meanwhile, British Columbia, Alberta, Quebec and New Brunswick, for example, leave this decision to the discretion of pharmacists, and only drugs listed on formularies are automatically included.

    Instead, we need all provinces to allow generic substitution to be readily available so employees and employers can save money on their drug plans.

    As Manulife said, “When it comes to your prescription drugs, why pay more than you have to?

    Jim Keon is president of the Canadian Generic Pharmaceutical Association.

    read more
    Generic drugs

    The pros and cons of generic drugs explored

    A patient who takes lorazepam (a generic version of Ativan) for her anxiety tells me that her medications have not worked as before in the past few months. She can’t identify what’s wrong, but she doesn’t like how it makes her feel. She thinks to herself that the pharmacy must have changed providers, but that shouldn’t really matter, because aren’t all generics supposed to work the same? Zoom in on some of the often overlooked facts about generic drugs.

    What are generic drugs?

    When a new drug is approved, it is patented for up to 20 years, giving the original manufacturer time and space in the market to recoup some of the costs of research and discovery. When the patent expires, other companies are allowed to manufacture a similar drug (a generic) that is “bioequivalent”, which means that it delivers the same active ingredient to the same part of the body, over the same length of time. than the original drug.

    Are Generic Drugs Less Expensive?

    The cost of producing a generic is much cheaper than the original, and competition from several manufacturers drives the price down even further. The price difference is greatest for drugs whose patents have long expired and whose market is dominated by generics. For example, the average monthly retail price of lorazepam is $ 24, compared to $ 1,386 for Ativan.

    Insurance companies encourage patients to choose generics with a lower co-payment and sometimes categorically refuse to cover brand-name drugs. On the other hand, pharmaceutical companies are offering coupons and discounts to offset the direct cost of brand name drugs in order to maintain their market share.

    Following:Health Matters: Let the Data Talk – Follow-up Questions on COVID Vaccines

    Who takes the generic drugs?

    Almost everybody. In 2020, 90% of all prescriptions in the United States were filled with generics, and that number has steadily increased since the Drug Price Competition and Patent Term Restoration Act of 1984. (also known as the Hatch-Waxman Act) opened the regulatory valve. in the manufacture of generic drugs. It is estimated that the use of generic drugs has saved Americans $ 313 billion a year in health care costs.

    Are there any downsides to generics?

    Quality control is a major concern. Companies reduce their costs by outsourcing production; the vast majority of generic drugs in America are made in India and China, while others rely on raw ingredients from these countries. Factories are not as frequently inspected by the FDA as those located in the United States and may not maintain the same level of production. Some unethical companies have even tampered with data to gain regulatory approval. In 2008, a Chinese batch of contaminated heparin, a crucial blood thinner for open heart surgery, killed at least 81 patients in America and injured hundreds more. Fortunately, these disasters are rare.

    More often than not, we see inconsistencies in the quality of generics and, therefore, in their biological effects. Unlike the single-source brand name drug, generics are produced by more than one company in more than one location. Pharmacies change supplier freely depending on price and / or availability. Even though the concentration of the active chemical remains the same, changing inactive ingredients like fillers, binders, and dyes can cause different reactions when you take the pill.

    Following:Don’t let the winter blues get you down, here’s how to stay cheerful in the dark months

    What should I do if my generic is not working properly?

    There are several options. Ask the pharmacist if a version of the medicine from the previous supplier is still available. Change your pharmacy, which will likely change providers. Some drugs have an “authorized generic” which is exactly the same as the brand name, produced by the same company and factory, but sold without the brand name. It is more expensive than other generics, but has quality assurance from the original pharmaceutical company. If you develop a true allergy or severe intolerance to generics, ask your doctor to specify “brand name only” on the prescription, although this may require passing certain hurdles for insurance to pay for it.

    Usually we don’t look twice at the pill bottle after filling a prescription. But as we strive to become more informed healthcare consumers, we hope this generic drug information will encourage you to take a closer look, and perhaps say “Yes” when the pharmacy cashier tells you. ask if you have any questions for the pharmacist about your medicine.

    Qing Yang and Kevin Parker are a married couple living in Springfield. Dr. Yang received her medical degree from Yale University School of Medicine and completed her residency at Massachusetts General Hospital. She is an anesthesiologist at HSHS Medical Group. Parker has helped formulate and administer public policy in various cities and state governments across the country. He was previously the Group Information Director for Education at the Illinois Department of Innovation and Technology. This column is not intended to be a substitute for professional medical advice, diagnosis or treatment. Opinions are those of the authors and do not represent the views of their employers.

    read more
    Generic drugs

    Online pharmacies could save Medicare billions on generic drugs

    PThe public outcry over the shockingly high cost of brand name drugs and the demand for new laws to limit the cost of these drugs has persisted for years. But more than 90% of all prescriptions – nearly 4 billion a year – are filled with generic drugs.

    Little attention has been paid to the fees charged by insurance companies, drug benefit managers, and pharmacies to fill these generic prescriptions. Yet the difference between the highest and lowest price charged for the same generic drug is so great that billions of dollars could be saved each year by having prescriptions filled at the cheapest pharmacies.

    The entry of companies like Amazon and GoodRx into the prescription fulfillment business is a game-changer. They offer prices far below what the federal government pays to insurance plans to have these prescriptions filled under Medicare Part D drug coverage. The repeal of the current design of Part D benefits and replacing it with a system in which the government directly reimburses low-cost pharmacies for filling generic prescriptions would save an estimated $18 billion a year. Patients would save an additional $8 billion in co-payments because the prices charged by these pharmacies do not require any form of insurance or additional co-payments.

    advertising

    I compiled information from the Medicare Part D website on the amount spent per pill for the top 20 selling generic drugs of 2019. I then determined how much Amazon and GoodRx charged for a 90 day prescription for the same 20 medications and calculated the cost per pill for these prescriptions. For example, Medicare paid 26 cents per pill for atorvastatin, the generic version of the cholesterol-lowering drug Lipitor. Amazon fills a 90-day prescription for a 20-milligram atorvastatin tablet, the most common dose, for $4.20. This equates to less than 5 cents per pill. The government paid $919 million to insurance plans to distribute 3.6 billion atorvastatin tablets in 2019. Amazon reportedly distributed these tablets for $182 million, a savings of $737 million on a single drug generic.

    As the chart here shows, Medicare spent $8.8 billion to distribute these 20 generic drugs in 2019. Amazon reportedly did this for just $4.6 billion and GoodRx for $5.1 billion. If the prescriptions had been filled by selecting the cheapest drug from Amazon or GoodRx, the cost would have been $3.5 billion. This represents a savings of $5.3 billion (60%) over what Medicare spent.

    advertising

    In 2019, Medicare Part D filled approximately 1.2 billion generic prescriptions at a total cost of approximately $30 billion. If the 60% savings applied to all generic drugs dispensed under Part D, the government would have saved $18 billion.

    In addition to overburdening the government, Part D insurance plans also charge patients co-payments for most generic prescriptions. Iqvia reports that 65% ($8 billion) of the $12 billion in Part D outlays paid by patients are for generic prescriptions. GoodRx estimates that its total price for filling generic prescriptions is less than the Medicare Part D copay about one-third of the time. The Amazon and GoodRx price is the total price of the drug. There is no quota. That means patients would save $8 billion in out-of-pocket costs, bringing the total savings from a Medicare drug benefit overhaul to $26 billion.

    How is it possible that the cost of filling generic prescriptions can vary so widely? The answer lies in a lack of transparency on the true cost of generic drugs. The World Health Organization estimates that generic versions of essential medicines can be produced cost-effectively with a 99% reduction in the cost of the brand name medicine. Thus, a patented pill that sells for $1 can be produced profitably and sold as a generic for a penny. In fact, generic manufacturers now sell many of the most widely prescribed generic drugs in the United States for 1 cent to 5 cents per pill.

    Competition among generic manufacturers ensures that these pills are offered for sale at a small profit compared to the actual cost of producing them. Yet in a few cases where such competition is lacking, as was the case with the generic version of the EpiPen, the cost of a generic drug may sell for only a small discount to the brand name product.

    Insurance plans and drug benefit managers price their generic prescriptions at levels that the market will bear rather than at a reasonable markup over the actual cost of acquiring and dispensing the prescription. Patients and payers think they’re getting a good deal when they get a 70% discount and pay 30 cents per pill for the generic version of a brand name drug they used to pay $1 for. They have no idea that the pharmacy bought this pill for just a penny or two and markup each pill 10 to 20 times its cost. The high markup imposed by insurance plans and drug benefit managers is why the government pays 26 cents a pill for atorvastatin while Amazon sells it for 5 cents.

    Discount pharmacies like Amazon disrupt the prescription drug market by pricing their prescriptions on a cost-plus basis while making a fair profit. A 90-day prescription for a generic drug acquired at a cost of 1 cent per pill has an ingredient cost of 90 cents. Average dispensing cost – the cost to the pharmacy for time spent counting and packaging pills, labeling pills, complying with prescription record keeping laws, and recording information required for reimbursement insurance plans – is about $2.40 per prescription. If a discount pharmacy charges $5.00 for this 90-day prescription, they will make a profit of $1.70 on the actual $3.30 cost of the prescription. This equates to a gross profit of 34%, which compares favorably to the reported profit margins of independent pharmacies.

    For a 90 day prescription, adding ten cents to the cost of each pill would add $9 to the cost of the prescription. That doesn’t sound like a lot, but doing this for 4 billion prescriptions translates to $36 billion.

    Medicare should be able to fill generic prescriptions at the lowest price charged for those prescriptions in the competitive retail market. But the 2003 law that created Part D prohibits the government from seeking the best price and gives private insurance plans exclusive power to set the price. The Republican administration that championed the enactment of Part D mistakenly believed that competition among insurance plans would result in the lowest prices and the widest choices for beneficiaries. No such competition ever materialized. Instead, Part D has created windfall profits for private insurance plans and drug benefit managers while adding unnecessary complexity to the generic prescription filling process. Patients are now faced with an incomprehensible array of forms, quantity limitations and co-payments that often make it cheaper to pay for a generic drug outright than to use Part D insurance.

    The current design of the Part D advantage is ill-suited to a world in which discount pharmacies fill prescriptions for generic drugs at affordable prices without insurance. A new design that cuts out costly middlemen and relies on price competition between pharmacies will not only dramatically reduce Part D costs, but will also force all pharmacies to cut their profit margins if they hope to compete for prescriptions of part D, which represent 30% of retail pharmacy activity.

    Part D prices for generic drugs would quickly become the benchmark for private payers and drive down prices and copayments for generic drug prescriptions in private insurance plans. The end result would be that more than 90% of all prescriptions could be filled at a lower cost to payers without imposing significant additional costs on patients.

    Senate Democrats are currently negotiating a $3.5 trillion soft infrastructure package that will include legislation to reduce patient out-of-pocket payments in Part D and expand Medicare to cover vision, dental and hearing services by mandating new taxes. My proposal to reduce the cost of Medicare for the distribution of generic drugs and the Biden administration’s proposal to limit price increases for brand name drugs could produce enough savings on the cost of current Medicare benefits for drugs on prescription to pay for the proposed expansion of Medicare benefits without these taxes.

    Given growing resistance from moderate Democrats to the $3.5 trillion price tag of the proposed infrastructure package, paying for new benefits by reducing the cost of existing ones may be the wisest course.

    Alfred Engelberg is a retired intellectual property lawyer and philanthropist who focuses on efforts to make health care and medicine more affordable. As legal counsel to the generic drug industry, he played a major role in drafting the Hatch-Waxman Act of 1984, which created the modern generic drug industry.

    read more
    Generic drugs

    OP-ED: Americans deserve public generic drugs – Orange Leader

    Bold policies could have saved America’s largest generic drug factory, but it’s never too late to start putting communities first.

    It’s an all-too-familiar story. A company with some of the highest paying jobs and a vital community anchor decides to engage in “restructuring” to “maximize long-term value creation”.

    In other words, it closes its doors and lays off its workers in search of bigger profits.

    But the late July closure of the Viatris pharmaceutical plant in Morgantown, West Virginia – which employed nearly 1,500 people and was the largest remaining generic pharmaceutical plant in the United States – is particularly infuriating.

    West Virginia Governor Jim Justice echoed a sentiment across the political spectrum when he said Aug. 4, “I think it’s pitiful, pitiful, absolutely pitiful that our federal government right now, with something as critical as pharmaceuticals are to our citizens, either just decide to sit on the sidelines and let this disaster happen.

    The shutdown was only preventable – if there had been federal or state action based on prioritizing protecting public health and economic well-being over short-term shareholder returns. We had the tools. All that was needed was the audacity and the political will to use them.

    The chain of events began in 2020 when factory owner Mylan (led by Heather Bresch, daughter of West Virginia Senator Joe Manchin) merged with Upjohn to form a new company, Viatris, creating the largest generics company in the world. Shortly after, Viatris announced a “restructuring initiative” which included closing some of its plants, including the Morgantown plant.

    The local Steelworkers representing many workers at the plant began calling on both the new Biden administration and state officials to keep the plant open. Their key argument was its role in the country’s pharmaceutical supply chain, especially in the context of the COVID-19 pandemic. The plant produced 18 billion doses of low-cost generics a year, including many essential drugs paid for through various federal programs.

    A letter to the Biden administration signed by the Steelworkers and about 40 other healthcare and advocacy groups (including The Democracy Collaborative, where I work) called for using the Defense Production Act to stop the plant shutdown .

    One of President Biden’s first executive orders called for using the law if necessary to “acquire additional inventory, improve distribution systems, build market capacity, or expand the industrial base.” But the Biden administration, like the Trump administration before it, did none of that in Morgantown.

    Keeping the Morgantown plant open would have been a clear case of ensuring local distribution and manufacturing capacity for a critical good: medicine. The designation the plant has already received from the Department of Homeland Security as critical infrastructure underscores this.

    The opportunity to explore a public ownership option in pharmaceuticals has been overlooked. Public enterprises are free from profit constraints and can instead define their bottom line by what they contribute to public health, scientific advancement, and local economic resilience.

    The payoffs for our communities would be enormous: Reliable access to affordable generics helps keep people out of hospitals and into jobs, schools and community service roles. Generics significantly reduce our overall health care costs. Additionally, manufacturing plants are vital economic engines as well as centers of local intellectual capital.

    It is encouraging that a public institution, West Virginia University, announced talks with Viatris to acquire the plant, but that was after hundreds of highly skilled workers were unnecessarily laid off, most of whom are eager to see if an agreement is reached before looking for New work.

    What we really need in the face of continued outsourcing and offshoring is a genuine industrial strategy that includes public ownership and puts community health above the demands of absentee shareholders.

    Dana Brown is director of the Next System Project of The Democracy Collaborative, “a research and development laboratory for the democratic economy”. This editorial was distributed by OtherWords.org.

    read more
    Generic drugs

    Consumer perception fuels brand wars and affects use of generic drugs, says CCI chief

    New Delhi: According to Ashok Kumar Gupta, Chairman of the Competition Commission of India (CCI), consumer perception of variation in efficacy is driving a brand war in the pharmaceutical retail market, diluting the chilling effect on the prices of drugs sold under their chemical or generic names.

    Gupta highlighted the role that generic drugs can play in creating the competitive pressures needed to lower prescription drug prices, reduce health care costs and improve access. However, Indian consumers are ostensibly paying a premium for brands, Gupta said at a CCI-hosted workshop on Friday on competition issues in the pharmaceutical sector. His comments were based on an interim market study conducted by the regulator.

    The pharmaceutical market is different from other markets as consumers often do not deviate from the brand prescribed by the doctor or opt for the same drug sold under its chemical name. This distorts competition in the market. Also, drug manufacturers market their products through physicians rather than directly to consumers.

    In India, generic drugs promoted by companies under their brand names are called branded generics and those sold under their chemical name are called “generic generics”, although both categories are off-patent drugs.

    On this issue of the prevalence of branded generics in the pharmaceutical retail market in India, Gupta highlighted the key role that quality expectations and the perception of efficacy variation between drugs play in fueling brand competition. and dilute the generic price reduction effect in India. India, said an official statement after the workshop. Apart from the quality aspect, he alluded to the important role that Janaushadhi and the emerging private generic retail chains in the country can play in increasing the availability and improving the uptake of generic generics, says the statement quoting Gupta.

    Vinod K. Paul, member of NITI Aayog, who spoke on the occasion, said that access to medicines without financial hardship and quality assurance were essential for universal health coverage.

    Considering that expenditure on drugs accounts for 70% of out-of-pocket healthcare expenditure in India, he stressed the importance of improving accessibility of drugs, according to the statement.

    Paul pointed out that streamlining the commercial margins of 42 cancer drugs on a pilot basis in 2019 led to cost savings of 984 crores for over 500 brands across 42 formulations. Paul further cited instances where margin rationalization resulted in a 90% price reduction on certain drugs, according to the release.

    To subscribe to Mint Bulletins

    * Enter a valid email address

    * Thank you for subscribing to our newsletter.

    Never miss a story! Stay connected and informed with Mint. Download our app now!!

    read more